| Year |
Citation |
Score |
| 2021 |
Kratz CP, Freycon C, Maxwell KN, Nichols KE, Schiffman JD, Evans DG, Achatz MI, Savage SA, Weitzel JN, Garber JE, Hainaut P, Malkin D. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis. Jama Oncology. PMID 34709361 DOI: 10.1001/jamaoncol.2021.4398 |
0.342 |
|
| 2021 |
Guzmán-Arocho YD, Rosenberg SM, Garber JE, Vardeh H, Poorvu PD, Ruddy KJ, Kirkner G, Snow C, Tamimi RM, Peppercorn J, Schapira L, Borges VF, Come SE, Brachtel EF, Marotti JD, et al. Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. British Journal of Cancer. PMID 34703009 DOI: 10.1038/s41416-021-01597-2 |
0.472 |
|
| 2021 |
Tutt ANJ, Garber JE, Geyer CE. Adjuvant Olaparib in BRCA-Mutated Breast Cancer. Reply. The New England Journal of Medicine. 385: 1440. PMID 34614338 DOI: 10.1056/NEJMc2112373 |
0.479 |
|
| 2021 |
Xu J, Keenan TE, Overmoyer B, Tung NM, Gelman RS, Habin K, Garber JE, Ellisen LW, Winer EP, Goss PE, Yeap BY, Chabner BA, Isakoff SJ. Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations. Breast Cancer Research and Treatment. PMID 34417675 DOI: 10.1007/s10549-021-06292-7 |
0.44 |
|
| 2021 |
Gallagher S, Hughes E, Kurian AW, Domchek SM, Garber J, Probst B, Morris B, Tshiaba P, Meek S, Rosenthal E, Roa B, Slavin TP, Wagner S, Weitzel J, Gutin A, et al. Comprehensive Breast Cancer Risk Assessment for and Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model. Jco Precision Oncology. 5. PMID 34322652 DOI: 10.1200/PO.20.00484 |
0.376 |
|
| 2021 |
Lakeman IMM, van den Broek AJ, Vos JAM, Barnes DR, Adlard J, Andrulis IL, Arason A, Arnold N, Arun BK, Balmaña J, Barrowdale D, Benitez J, Borg A, Caldés T, Caligo MA, ... ... Garber J, et al. The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 34113011 DOI: 10.1038/s41436-021-01198-7 |
0.459 |
|
| 2021 |
Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, et al. Adjuvant Olaparib for Patients with - or -Mutated Breast Cancer. The New England Journal of Medicine. PMID 34081848 DOI: 10.1056/NEJMoa2105215 |
0.473 |
|
| 2021 |
Hughes E, Tshiaba P, Wagner S, Judkins T, Rosenthal E, Roa B, Gallagher S, Meek S, Dalton K, Hedegard W, Adami CA, Grear DF, Domchek SM, Garber J, Lancaster JM, et al. Integrating Clinical and Polygenic Factors to Predict Breast Cancer Risk in Women Undergoing Genetic Testing. Jco Precision Oncology. 5. PMID 34036224 DOI: 10.1200/PO.20.00246 |
0.407 |
|
| 2021 |
Coignard J, Lush M, Beesley J, O'Mara TA, Dennis J, Tyrer JP, Barnes DR, McGuffog L, Leslie G, Bolla MK, Adank MA, Agata S, Ahearn T, Aittomäki K, Andrulis IL, ... ... Garber J, et al. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications. 12: 2986. PMID 33990587 DOI: 10.1038/s41467-021-23162-4 |
0.453 |
|
| 2021 |
Coignard J, Lush M, Beesley J, O'Mara TA, Dennis J, Tyrer JP, Barnes DR, McGuffog L, Leslie G, Bolla MK, Adank MA, Agata S, Ahearn T, Aittomäki K, Andrulis IL, ... ... Garber J, et al. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications. 12: 1078. PMID 33597508 DOI: 10.1038/s41467-020-20496-3 |
0.404 |
|
| 2021 |
Tutt A, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmana Gelpi J, Gelmon KA, Baker N, Arahmani A, Senkus-Konefka E, Mc Fadden E, et al. OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer. Journal of Clinical Oncology. 39: LBA1-LBA1. DOI: 10.1200/JCO.2021.39.15_SUPPL.LBA1 |
0.309 |
|
| 2021 |
Yap TA, Ashok A, Stoll J, Schwarzbach AE, Blackwell KL, Li T, Kang H, Garber JE, Meric-Bernstam F. Rate of incidental germline findings detected by tumor-normal matched sequencing in cancer types lacking hereditary cancer testing guidelines. Journal of Clinical Oncology. 39: 10582-10582. DOI: 10.1200/JCO.2021.39.15_SUPPL.10582 |
0.381 |
|
| 2021 |
Bychkovsky BL, Li T, Sotelo J, Tayob N, Mercado J, Gomy I, Chittenden AB, Kane SR, Stokes S, Hughes ME, Kim JS, Awad MM, Konstantinopoulos PA, Wolpin BM, Taplin M, ... ... Garber JE, et al. Identification and management of pathogenic mutations in BRCA1, BRCA2, and PALB2 in a tumor-only genomic testing program. Journal of Clinical Oncology. 39: 10528-10528. DOI: 10.1200/JCO.2021.39.15_SUPPL.10528 |
0.347 |
|
| 2021 |
Garber J. Genetic testing in patients with triple negative or hereditary breast Cancer The Breast. 56: S6. DOI: 10.1016/S0960-9776(21)00061-8 |
0.437 |
|
| 2020 |
Bhatia S, Palomares MR, Hageman L, Chen Y, Landier W, Adams K, Umphrey H, Reich CA, Zamora KW, Armenian SH, Bevers TB, Blaes AH, Henderson TO, Hodgson DC, Hudson MM, ... ... Garber JE, et al. A Randomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated Cancer Survivors at risk for Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33272980 DOI: 10.1158/1078-0432.CCR-20-3609 |
0.456 |
|
| 2020 |
Rana HQ, Kipnis L, Hehir K, Cronin A, Jaung T, Stokes SM, Fekrmandi F, Vatnick D, Matulonis UA, Garber JE, Wright AA. Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer. Gynecologic Oncology. PMID 33229043 DOI: 10.1016/j.ygyno.2020.11.003 |
0.301 |
|
| 2020 |
Tung NM, Robson ME, Ventz S, Santa-Maria CA, Nanda R, Marcom PK, Shah PD, Ballinger TJ, Yang ES, Vinayak S, Melisko M, Brufsky A, DeMeo M, Jenkins C, Domchek S, ... ... Garber JE, et al. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2002151. PMID 33119476 DOI: 10.1200/JCO.20.02151 |
0.383 |
|
| 2020 |
Muranen TA, Khan S, Fagerholm R, Aittomäki K, Cunningham JM, Dennis J, Leslie G, McGuffog L, Parsons MT, Simard J, Slager S, Soucy P, Easton DF, Tischkowitz M, Spurdle AB, ... ... Garber J, et al. Association of germline variation with the survival of women with pathogenic variants and breast cancer. Npj Breast Cancer. 6: 44. PMID 32964118 DOI: 10.1038/s41523-020-00185-6 |
0.416 |
|
| 2020 |
Maxwell KN, Wenz BM, Kulkarni A, Wubbenhorst B, D'Andrea K, Weathers B, Goodman N, Vijai J, Lilyquist J, Hart SN, Slavin TP, Schrader KA, Ravichandran V, Thomas T, Hu C, ... ... Garber JE, et al. Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. Jco Precision Oncology. 4. PMID 32954205 DOI: 10.1200/PO.19.00301 |
0.504 |
|
| 2020 |
Hughes E, Tshiaba P, Gallagher S, Wagner S, Judkins T, Roa B, Rosenthal E, Domchek S, Garber J, Lancaster J, Weitzel J, Kurian AW, Lanchbury JS, Gutin A, Robson M. Development and Validation of a Clinical Polygenic Risk Score to Predict Breast Cancer Risk. Jco Precision Oncology. 4. PMID 32923876 DOI: 10.1200/PO.19.00360 |
0.481 |
|
| 2020 |
Underhill-Blazey M, Blonquist T, Chittenden A, Pozzar R, Nayak M, Lansang K, Hong F, Garber J, Stopfer JE. Informing models of cancer genetic care in the era of multigene panel testing with patient-led recommendations. Journal of Genetic Counseling. PMID 32851753 DOI: 10.1002/Jgc4.1317 |
0.328 |
|
| 2020 |
Gao F, Pan X, Dodd-Eaton EB, Recio CV, Montierth MD, Bojadzieva J, Mai PL, Zelley K, Johnson VE, Braun D, Nichols KE, Garber JE, Savage SA, Strong LC, Wang W. A pedigree-based prediction model identifies carriers of deleterious de novo mutations in families with Li-Fraumeni syndrome. Genome Research. PMID 32817165 DOI: 10.1101/Gr.249599.119 |
0.381 |
|
| 2020 |
Wood ME, McKinnon W, Garber J. Risk for breast cancer and management of unaffected individuals with non-BRCA hereditary breast cancer. The Breast Journal. PMID 32741080 DOI: 10.1111/Tbj.13969 |
0.444 |
|
| 2020 |
Barnes DR, Rookus MA, McGuffog L, Leslie G, Mooij TM, Dennis J, Mavaddat N, Adlard J, Ahmed M, Aittomäki K, Andrieu N, Andrulis IL, Arnold N, Arun BK, Azzollini J, ... ... Garber J, et al. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 32665703 DOI: 10.1038/S41436-020-0862-X |
0.456 |
|
| 2020 |
Kuba MG, Lester SC, Bowman T, Stokes SM, Taneja KL, Garber JE, Dillon DA. Histopathologic features of breast cancer in Li-Fraumeni syndrome. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 32636452 DOI: 10.1038/s41379-020-0610-4 |
0.384 |
|
| 2020 |
Gallagher S, Hughes E, Wagner S, Tshiaba P, Rosenthal E, Roa BB, Kurian AW, Domchek SM, Garber J, Lancaster J, Weitzel JN, Gutin A, Lanchbury JS, Robson M. Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes. Jama Network Open. 3: e208501. PMID 32609350 DOI: 10.1001/jamanetworkopen.2020.8501 |
0.453 |
|
| 2020 |
Patel JM, Goss A, Garber JE, Torous V, Richardson ET, Haviland MJ, Hacker MR, Freeman GJ, Nalven T, Alexander B, Lee L, Collins LC, Schnitt SJ, Tung N. Retinoblastoma protein expression and its predictors in triple-negative breast cancer. Npj Breast Cancer. 6: 19. PMID 32550264 DOI: 10.1038/s41523-020-0160-4 |
0.302 |
|
| 2020 |
Fortuno C, Mester J, Pesaran T, Weitzel JN, Dolinsky J, Yussuf A, McGoldrick K, Garber JE, Savage SA, Khincha PP, Gareth Evans D, Achatz MI, Nichols KE, Maxwell K, Schiffman JD, et al. Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelines. Human Mutation. PMID 32485079 DOI: 10.1002/humu.24060 |
0.366 |
|
| 2020 |
Zhang H, Ahearn TU, Lecarpentier J, Barnes D, Beesley J, Qi G, Jiang X, O'Mara TA, Zhao N, Bolla MK, Dunning AM, Dennis J, Wang Q, Ful ZA, Aittomäki K, ... ... Garber J, et al. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics. PMID 32424353 DOI: 10.1038/s41588-020-0609-2 |
0.43 |
|
| 2020 |
Kotsopoulos J, McGee EE, Lozano-Esparza S, Garber JE, Ligibel J, Collins LC, Polyak K, Brown M, Narod S, Tamimi RM, Eliassen AH. Premenopausal plasma osteoprotegerin and breast cancer risk: a case-control analysis nested within the Nurses' Health Study II. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 32277005 DOI: 10.1158/1055-9965.Epi-19-1154 |
0.375 |
|
| 2020 |
Daly MB, Pilarski R, Yurgelun MB, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Garber JE, Goggins M, Hutton ML, Khan S, Klein C, Kohlmann W, et al. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. Journal of the National Comprehensive Cancer Network : Jnccn. 18: 380-391. PMID 32259785 DOI: 10.6004/Jnccn.2020.0017 |
0.443 |
|
| 2020 |
Feng H, Gusev A, Pasaniuc B, Wu L, Long J, Abu-Full Z, Aittomäki K, Andrulis IL, Anton-Culver H, Antoniou AC, Arason A, Arndt V, Aronson KJ, Arun BK, Asseryanis E, ... ... Garber J, et al. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. Genetic Epidemiology. PMID 32115800 DOI: 10.1002/gepi.22288 |
0.439 |
|
| 2020 |
Yang X, Song H, Leslie G, Engel C, Hahnen E, Auber B, Horváth J, Kast K, Niederacher D, Turnbull C, Houlston R, Hanson H, Loveday C, Dolinsky JS, LaDuca H, ... ... Garber J, et al. Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D. Journal of the National Cancer Institute. PMID 32107557 DOI: 10.1093/Jnci/Djaa030 |
0.447 |
|
| 2020 |
Tung N, Arun B, Hacker MR, Hofstatter E, Toppmeyer DL, Isakoff SJ, Borges V, Legare RD, Isaacs C, Wolff AC, Marcom PK, Mayer EL, Lange PB, Goss AJ, Jenkins C, ... ... Garber JE, et al. TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline Carriers With HER2-Negative Breast Cancer (the INFORM trial). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1903292. PMID 32097092 DOI: 10.1200/JCO.19.03292 |
0.43 |
|
| 2020 |
Yurgelun MB, Uno H, Furniss CS, Ukaegbu CI, Horiguchi M, Chittenden AB, Fehlmann T, Yussuf A, LaDuca H, Garber JE, Syngal S. Development and validation of the PREMMplus clinical prediction model for multigene hereditary cancer risk assessment. Journal of Clinical Oncology. 38: 1579-1579. DOI: 10.1200/jco.2020.38.15_suppl.1579 |
0.354 |
|
| 2020 |
Gallagher S, Hughes E, Kurian AW, Domchek SM, Garber JE, Probst B, Morris B, Tshiaba P, Rosenthal ET, Roa B, Wagner S, Gutin A, Weitzel JN, Lanchbury J, Robson ME. Comprehensive breast cancer (BC) risk assessment for CHEK2 carriers incorporating a polygenic risk score (PRS) and the Tyrer-Cuzick (TC) model. Journal of Clinical Oncology. 38: 1504-1504. DOI: 10.1200/jco.2020.38.15_suppl.1504 |
0.32 |
|
| 2020 |
Tung NM, Robson ME, Ventz S, Santa-Maria CA, Marcom PK, Nanda R, Shah PD, Ballinger TJ, Yang ES, Melisko ME, Brufsky A, Vinayak S, Demeo M, Jenkins C, Domchek SM, ... ... Garber JE, et al. TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded). Journal of Clinical Oncology. 38: 1002-1002. DOI: 10.1200/Jco.2020.38.15_Suppl.1002 |
0.371 |
|
| 2020 |
Gallagher S, Hughes E, Wagner S, Tshiaba P, Rosenthal E, Roa BB, Kurian A, Domchek S, Garber J, Lancaster JM, Weitzel J, Gutin A, Lanchbury JS, Robson M. Abstract P6-08-07: Polygenic breast cancer risk modification in carriers of high and intermediate risk gene mutations Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P6-08-07 |
0.502 |
|
| 2020 |
Guerriero JL, Mehta AK, Cheney EM, Castrillon JA, Lin J, Taveira MdO, Sonzogni O, Pantelidou C, Hartl CA, Oldham WM, Johnson NT, Boswell SA, Kalocsay M, Berberich MJ, Mei S, ... ... Garber JE, et al. Abstract P5-04-01: PARP inhibition modulates the infiltration, phenotype and function of tumor-associated macrophages (TAMs) in BRCA-associated breast cancer and can be augmented by harnessing the anti-tumor potential of TAMs Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P5-04-01 |
0.314 |
|
| 2020 |
Arun BK, Gierach G, Scoggins ME, Khan S, Rao SS, Garber J, Raza S, Kumar NB, Han HH, Heine J, Niell B, Chalasani P, Fitzpatrick K, Wilke LG, Fowler A, et al. Abstract OT3-15-02: A randomized, double-blind, placebo-controlled study of 4-hydroxytamoxifen topical gel in women with mammographically dense breasts Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Ot3-15-02 |
0.385 |
|
| 2019 |
Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, Dunning AM, Redman J, Scarth J, Plaskocinska I, Luccarini C, Shah M, Pooley K, Dorling L, Lee A, ... ... Garber J, et al. Cancer Risks Associated With Germline Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1901907. PMID 31841383 DOI: 10.1200/Jco.19.01907 |
0.43 |
|
| 2019 |
Telli ML, Chu C, Badve SS, Vinayak S, Silver DP, Isakoff SJ, Kaklamani V, Gradishar W, Stearns V, Connolly RM, Ford JM, Gruber JJ, Adams S, Garber J, Tung N, et al. Association of Tumor Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31796517 DOI: 10.1158/1078-0432.Ccr-19-0664 |
0.381 |
|
| 2019 |
Figlioli G, Bogliolo M, Catucci I, Caleca L, Lasheras SV, Pujol R, Kiiski JI, Muranen TA, Barnes DR, Dennis J, Michailidou K, Bolla MK, Leslie G, Aalfs CM, ... ... Garber J, et al. The :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer. 5: 38. PMID 31700994 DOI: 10.1038/s41523-019-0127-5 |
0.452 |
|
| 2019 |
Song Y, Barry WT, Seah DS, Tung NM, Garber JE, Lin NU. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers. Cancer. PMID 31581314 DOI: 10.1002/Cncr.32540 |
0.443 |
|
| 2019 |
Batalini F, Peacock EG, Stobie L, Robertson A, Garber J, Weitzel JN, Tung NM. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis. Breast Cancer Research : Bcr. 21: 107. PMID 31533767 DOI: 10.1186/S13058-019-1193-1 |
0.454 |
|
| 2019 |
Ding L, Su Y, Fassl A, Hinohara K, Qiu X, Harper NW, Huh SJ, Bloushtain-Qimron N, Jovanović B, Ekram M, Zi X, Hines WC, Alečković M, Gil Del Alcazar C, Caulfield RJ, ... ... Garber JE, et al. Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ. Nature Communications. 10: 4182. PMID 31519911 DOI: 10.1038/S41467-019-12125-5 |
0.389 |
|
| 2019 |
Hamilton JG, Long JM, Brandt AC, Brower J, Symecko H, Salo-Mullen EE, Christian SN, Harstad T, Couch FJ, Garber JE, Offit K, Robson ME, Domchek SM. Patients' Medical and Psychosocial Experiences After Detection of a Variant With Multigene Panel Testing. Jco Precision Oncology. 3. PMID 31511843 DOI: 10.1200/PO.18.00300 |
0.315 |
|
| 2019 |
Visvanathan K, Fabian CJ, Bantug E, Brewster AM, Davidson NE, DeCensi A, Floyd JD, Garber JE, Hofstatter EW, Khan SA, Katapodi MC, Pruthi S, Raab R, Runowicz CD, Somerfield MR. Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1901472. PMID 31479306 DOI: 10.1200/Jco.19.01472 |
0.425 |
|
| 2019 |
Tang R, Acevedo F, Lanahan C, Coopey SB, Yala A, Barzilay R, Li C, Colwell A, Guidi AJ, Cetrulo C, Garber J, Smith BL, Gadd MA, Specht MC, Hughes KS. Incidental breast carcinoma: incidence, management, and outcomes in 4804 bilateral reduction mammoplasties. Breast Cancer Research and Treatment. PMID 31317348 DOI: 10.1007/S10549-019-05335-4 |
0.326 |
|
| 2019 |
Wood ME, Garber JE, Isaacs C, Masood S, Bedrosian I, Tung N, Chun J, Schnabel FR, Arun BK. Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations. The Breast Journal. 25: 575-577. PMID 31280501 DOI: 10.1111/tbj.13292 |
0.451 |
|
| 2019 |
Dayan E, Chittenden A, Garber JE, Wo L, Caterson SA, Carty MJ, Erdmann-Sager J. Genetic Testing for Breast Cancer Susceptibility Should Be Offered before Unilateral Abdominally Based Free Flap Breast Reconstruction. Plastic and Reconstructive Surgery. 144: 12-20. PMID 31246791 DOI: 10.1097/PRS.0000000000005693 |
0.396 |
|
| 2019 |
Qian F, Rookus MA, Leslie G, Risch HA, Greene MH, Aalfs CM, Adank MA, Adlard J, Agnarsson BA, Ahmed M, Aittomäki K, Andrulis IL, Arnold N, Arun BK, Ausems MGEM, ... ... Garber J, et al. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer. PMID 31213659 DOI: 10.1038/S41416-019-0492-8 |
0.336 |
|
| 2019 |
Chi D, Singhal H, Li L, Xiao T, Liu W, Pun M, Jeselsohn R, He H, Lim E, Vadhi R, Rao P, Long H, Garber J, Brown M. Estrogen receptor signaling is reprogrammed during breast tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America. PMID 31110002 DOI: 10.1073/Pnas.1819155116 |
0.382 |
|
| 2019 |
Ferreira MA, Gamazon ER, Al-Ejeh F, Aittomäki K, Andrulis IL, Anton-Culver H, Arason A, Arndt V, Aronson KJ, Arun BK, Asseryanis E, Azzollini J, Balmaña J, Barnes DR, Barrowdale D, ... ... Garber J, et al. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications. 10: 1741. PMID 30988301 DOI: 10.1038/s41467-018-08053-5 |
0.434 |
|
| 2019 |
Rana HQ, Sacca R, Drogan C, Gutierrez S, Schlosnagle E, Regan MM, Speare V, LaDuca H, Dolinsky J, Garber JE, Overmoyer BA. Prevalence of germline variants in inflammatory breast cancer. Cancer. PMID 30933323 DOI: 10.1002/cncr.32062 |
0.458 |
|
| 2019 |
Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesseur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G, Gaudet MM, Huyghe JR, Albanes D, ... ... Garber J, et al. Shared heritability and functional enrichment across six solid cancers. Nature Communications. 10: 431. PMID 30683880 DOI: 10.1038/S41467-018-08054-4 |
0.407 |
|
| 2019 |
Weiss A, Grossmith S, Cutts D, Mikami SA, Suskin JA, Graichen MK, Rojas NA, Pace LE, Joyce E, Rhei E, Scheib R, Bychkovsky B, Garber JE, Morganstern D, King TA. Customized breast cancer risk assessment in an ambulatory clinic: a portal for identifying women at risk. Breast Cancer Research and Treatment. PMID 30666540 DOI: 10.1007/s10549-018-05116-5 |
0.326 |
|
| 2019 |
Coopey SB, Kartal K, Li C, Yala A, Barzilay R, Faulkner HR, King TA, Acevedo F, Garber JE, Guidi AJ, Hughes KS. Atypical ductal hyperplasia in men with gynecomastia: what is their breast cancer risk? Breast Cancer Research and Treatment. PMID 30666539 DOI: 10.1007/S10549-018-05117-4 |
0.433 |
|
| 2019 |
Vatnick DR, Aktar S, Stopfer JE, Kipnis L, Culver SK, Koeller DR, Husband AE, Allen K, Kilbridge KL, McGregor BA, Sweeney C, Speare V, Tippin Davis B, Dolinsky JS, Garber JE, et al. Genetic counseling processes and outcomes among prostate cancer patients (ProGen). Journal of Clinical Oncology. 37: TPS343-TPS343. DOI: 10.1200/JCO.2019.37.7_SUPPL.TPS343 |
0.379 |
|
| 2019 |
Acevedo F, Armengol VD, Deng Z, Tang R, Coopey S, Mazzola E, Lanahan C, Braun D, Yala A, Barzilay R, Li C, Santus E, Colwell A, Guidi A, Cetrulo C, ... Garber JE, et al. Incidental atypical hyperplasia/LCIS in mammoplasty specimens and subsequent risk of breast cancer. Journal of Clinical Oncology. 37: 1561-1561. DOI: 10.1200/Jco.2019.37.15_Suppl.1561 |
0.348 |
|
| 2019 |
Culver S, Kipnis L, Stokes S, Bychkovsky B, Scheib R, Rana H, Garber J. Abstract P4-03-02: Casting a wide net: Finding actionable results in non-breast cancer (BC) genes on multi-gene panel testing (MGPT) in a BC cohort Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P4-03-02 |
0.365 |
|
| 2019 |
Warren L, Iannone A, Punglia RS, Wong JS, Garber J, Bellon JR. Radiation-Related Toxicities in Patients with Known Pathogenic Mutations in Cancer Susceptibility Genes Treated Definitively for Breast Cancer International Journal of Radiation Oncology Biology Physics. 105. DOI: 10.1016/J.Ijrobp.2019.06.252 |
0.444 |
|
| 2018 |
Cline MS, Liao RG, Parsons MT, Paten B, Alquaddoomi F, Antoniou A, Baxter S, Brody L, Cook-Deegan R, Coffin A, Couch FJ, Craft B, Currie R, Dlott CC, Dolman L, ... ... Garber J, et al. BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. Plos Genetics. 14: e1007752. PMID 30586411 DOI: 10.1371/Journal.Pgen.1007752 |
0.356 |
|
| 2018 |
Bevers TB, Helvie M, Bonaccio E, Calhoun KE, Daly MB, Farrar WB, Garber JE, Gray R, Greenberg CC, Greenup R, Hansen NM, Harris RE, Heerdt AS, Helsten T, Hodgkiss L, et al. Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 16: 1362-1389. PMID 30442736 DOI: 10.6004/jnccn.2018.0083 |
0.398 |
|
| 2018 |
Qian F, Wang S, Mitchell J, McGuffog L, Barrowdale D, Leslie G, Oosterwijk JC, Chung WK, Evans DG, Engel C, Kast K, Aalfs CM, Adank MA, Adlard J, Agnarsson BA, ... ... Garber J, et al. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute. PMID 30312457 DOI: 10.1093/jnci/djy132 |
0.45 |
|
| 2018 |
Cruz C, Llop-Guevara A, Garber JE, Arun BK, Pérez Fidalgo JA, Lluch A, Telli ML, Fernández C, Kahatt C, Galmarini CM, Soto-Matos A, Alfaro V, Pérez de la Haza A, Domchek SM, Antolin S, et al. Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018786558. PMID 30240327 DOI: 10.1200/JCO.2018.78.6558 |
0.387 |
|
| 2018 |
Acevedo F, Armengol VD, Deng Z, Tang R, Coopey SB, Braun D, Yala A, Barzilay R, Li C, Colwell A, Guidi A, Cetrulo CL, Garber J, Smith BL, King T, et al. Pathologic findings in reduction mammoplasty specimens: a surrogate for the population prevalence of breast cancer and high-risk lesions. Breast Cancer Research and Treatment. PMID 30238276 DOI: 10.1007/S10549-018-4962-0 |
0.394 |
|
| 2018 |
Weiss A, Garber JE, King T. Breast Cancer Surgical Risk Reduction for Patients With Inherited Mutations in Moderate Penetrance Genes. Jama Surgery. PMID 30167656 DOI: 10.1001/jamasurg.2018.2493 |
0.462 |
|
| 2018 |
Shimelis H, LaDuca H, Hu C, Hart SN, Na J, Thomas A, Akinhanmi M, Moore RM, Brauch H, Cox A, Eccles DM, Ewart-Toland A, Fasching PA, Fostira F, Garber J, et al. Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing. Journal of the National Cancer Institute. PMID 30099541 DOI: 10.1093/Jnci/Djy106 |
0.463 |
|
| 2018 |
Tung NM, Garber JE. BRCA1/2 testing: therapeutic implications for breast cancer management. British Journal of Cancer. PMID 29867226 DOI: 10.1038/s41416-018-0127-5 |
0.505 |
|
| 2018 |
Pathania S, Garber JE. Mixing Mutation Location With Carcinogen Exposure: A Recipe for Tissue Specificity in BRCA2-Associated Cancers? Journal of the National Cancer Institute. PMID 29767746 DOI: 10.1093/Jnci/Djy047 |
0.314 |
|
| 2018 |
Borgquist S, Hall P, Lipkus I, Garber JE. Towards Prevention of Breast Cancer: What Are the Clinical Challenges? Cancer Prevention Research (Philadelphia, Pa.). PMID 29661853 DOI: 10.1158/1940-6207.CAPR-16-0254 |
0.446 |
|
| 2018 |
Gucalp A, Zhou XK, Cook ED, Garber JE, Crew KD, Nangia JR, Bhardwaj P, Giri DD, Elemento O, Verma A, Wang H, Lee JJ, Vornik LA, Mays C, Weber D, et al. A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions or Benign Breast Disease. Cancer Prevention Research (Philadelphia, Pa.). PMID 29453232 DOI: 10.1158/1940-6207.CAPR-17-0354 |
0.332 |
|
| 2018 |
Birkbak NJ, Li Y, Pathania S, Greene-Colozzi A, Dreze M, Bowman-Colin C, Sztupinszki Z, Krzystanek M, Diossy M, Tung N, Ryan PD, Garber JE, Silver DP, Iglehart JD, Wang ZC, et al. Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple negative breast and serous ovarian cancers. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29452344 DOI: 10.1093/Annonc/Mdy049 |
0.397 |
|
| 2018 |
Acevedo F, Tang R, Coopey S, Yala A, Barzilay R, Li C, Colwell A, Guidi A, Cetrulo C, Garber JE, Smith BL, Gadd M, Specht MC, Gudewicz T, Braun D, et al. Pathologic findings in reduction mammoplasty procedures identified by natural language processing of breast pathology reports: A surrogate for the population incidence of cancer and high risk lesions. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E13569 |
0.376 |
|
| 2018 |
Hamilton J, Long JM, Brandt AC, Brower J, Symecko H, Salo-Mullen EE, Christian S, Couch F, Garber JE, Offit K, Robson ME, Domchek SM. Examining patients’ medical and psychosocial experiences following detection of a CDH1 variant with multiplex genetic testing. Journal of Clinical Oncology. 36: 1583-1583. DOI: 10.1200/Jco.2018.36.15_Suppl.1583 |
0.322 |
|
| 2018 |
Rosenbluth JM, Schackmann R, Li C, Sachs N, Dillon D, Richardson A, Brock J, Garber J, Gray GK, Zoeller J, Boedicker M, Kuiken HJ, Clevers H, Brugge J. Abstract 989: Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages and can form chimeric mammary glands in vivo Cancer Research. 78: 989-989. DOI: 10.1158/1538-7445.Am2018-989 |
0.329 |
|
| 2017 |
Slavin TP, Maxwell KN, Lilyquist J, Vijai J, Neuhausen SL, Hart SN, Ravichandran V, Thomas T, Maria A, Villano D, Schrader KA, Moore R, Hu C, Wubbenhorst B, Wenz BM, ... ... Garber JE, et al. Erratum: Author Correction: The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. Npj Breast Cancer. 3: 44. PMID 29119134 DOI: 10.1038/s41523-017-0046-2 |
0.447 |
|
| 2017 |
O'Neill AF, Voss SD, Jagannathan JP, Kamihara J, Nibecker C, Itriago-Araujo E, Masciari S, Parker E, Barreto M, London WB, Garber JE, Diller L. Screening with whole-body magnetic resonance imaging in pediatric subjects with Li-Fraumeni syndrome: A single institution pilot study. Pediatric Blood & Cancer. PMID 29077256 DOI: 10.1002/pbc.26822 |
0.302 |
|
| 2017 |
Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, Lindström S, Hui S, Lemaçon A, Soucy P, Dennis J, Jiang X, Rostamianfar A, Finucane H, Bolla MK, McGuffog L, ... ... Garber J, et al. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics. PMID 29058716 DOI: 10.1038/Ng.3785 |
0.482 |
|
| 2017 |
Han HS, Diéras V, Robson M, Palácová M, Marcom PK, Jager A, Bondarenko I, Citrin D, Campone M, Telli ML, Domchek SM, Friedlander M, Kaufman B, Garber JE, Shparyk Y, et al. Veliparib With Temozolomide or Carboplatin/Paclitaxel Versus Placebo With Carboplatin/Paclitaxel in Patients With BRCA1/2 Locally Recurrent/Metastatic Breast Cancer: Randomized Phase II Study. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29045554 DOI: 10.1093/annonc/mdx505 |
0.376 |
|
| 2017 |
Hu Y, Alden RS, Odegaard JI, Fairclough SR, Chen R, Heng J, Feeney N, Nagy R, Shah J, Ulrich B, Gutierrez M, Lanman RB, Garber JE, Paweletz CP, Oxnard GR. Discrimination of germline EGFR T790M mutations in plasma cell-free DNA allows study of prevalence across 31,414 cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28947568 DOI: 10.1158/1078-0432.Ccr-17-1745 |
0.323 |
|
| 2017 |
Nurudeen S, Guo H, Chun Y, Coopey S, Barry W, Garber J, Dominici LS. Patient experience with breast reconstruction process following bilateral mastectomy in BRCA mutation carriers. American Journal of Surgery. PMID 28683895 DOI: 10.1016/J.Amjsurg.2017.06.017 |
0.37 |
|
| 2017 |
Slavin TP, Maxwell KN, Lilyquist J, Vijai J, Neuhausen SL, Hart SN, Ravichandran V, Thomas T, Maria A, Villano D, Schrader KA, Moore R, Hu C, Wubbenhorst B, Wenz BM, ... ... Garber JE, et al. The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. Npj Breast Cancer. 3: 22. PMID 28649662 DOI: 10.1038/s41523-017-0024-8 |
0.521 |
|
| 2017 |
Pomerantz MM, Spisák S, Jia L, Cronin AM, Csabai I, Ledet E, Sartor AO, Rainville I, O'Connor EP, Herbert ZT, Szállási Z, Oh WK, Kantoff PW, Garber JE, Schrag D, et al. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer. PMID 28608931 DOI: 10.1002/cncr.30808 |
0.413 |
|
| 2017 |
Mazzola E, Coopey SB, Griffin M, Polubriaginof F, Buckley JM, Parmigiani G, Garber JE, Smith BL, Gadd MA, Specht MC, Guidi A, Hughes KS. Reassessing risk models for atypical hyperplasia: age may not matter. Breast Cancer Research and Treatment. PMID 28589368 DOI: 10.1007/S10549-017-4320-7 |
0.318 |
|
| 2017 |
Kratz CP, Achatz MI, Brugières L, Frebourg T, Garber JE, Greer MC, Hansford JR, Janeway KA, Kohlmann WK, McGee R, Mullighan CG, Onel K, Pajtler KW, Pfister SM, Savage SA, et al. Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 23: e38-e45. PMID 28572266 DOI: 10.1158/1078-0432.Ccr-17-0408 |
0.381 |
|
| 2017 |
Peters ML, Garber JE, Tung N. Managing hereditary breast cancer risk in women with and without ovarian cancer. Gynecologic Oncology. PMID 28454658 DOI: 10.1016/j.ygyno.2017.04.013 |
0.514 |
|
| 2017 |
Borgquist S, Giobbie-Hurder A, Ahern TP, Garber JE, Colleoni M, Láng I, Debled M, Ejlertsen B, von Moos R, Smith I, Coates AS, Goldhirsch A, Rabaglio M, Price KN, Gelber RD, et al. Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 35: 1179-1188. PMID 28380313 DOI: 10.1200/Jco.2016.70.3116 |
0.377 |
|
| 2017 |
Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, Giannakis M, Shilatifard A, Finn OJ, Dhodapkar M, Kay NE, Braggio E, Vilar E, Mazzilli SA, Rebbeck TR, ... Garber JE, et al. Precancer Atlas to Drive Precision Prevention Trials. Cancer Research. 77: 1510-1541. PMID 28373404 DOI: 10.1158/0008-5472.Can-16-2346 |
0.369 |
|
| 2017 |
Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, Garber JE, Kauff ND, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, Merajver SD, et al. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. Journal of the National Comprehensive Cancer Network : Jnccn. 15: 9-20. PMID 28040716 DOI: 10.6004/Jnccn.2017.0003 |
0.438 |
|
| 2017 |
Kamihara J, LaDuca H, Dalton E, Speare V, Garber JE, Black MH. Germline mutations in cancer predisposition genes among patients with thyroid cancer. Journal of Clinical Oncology. 35: 1581-1581. DOI: 10.1200/Jco.2017.35.15_Suppl.1581 |
0.467 |
|
| 2017 |
Chen R, Koeller DR, Sholl LM, Rabin MS, Yurgelun MB, Chittenden AB, Garber JE, Oxnard GR. Routine tumor next-generation sequencing (NGS) to identify rare germline lung cancer risk mutations in EGFR and ERBB2. Journal of Clinical Oncology. 35: 1513-1513. DOI: 10.1200/JCO.2017.35.15_SUPPL.1513 |
0.331 |
|
| 2017 |
Patel JM, Torous V, Hacker MR, Nalven T, Garber JE, Alexander BM, Lee LJ, Collins LC, Schnitt SJ, Tung NM. Retinoblastoma (Rb) protein expression in triple-negative breast cancer. Journal of Clinical Oncology. 35: 1097-1097. DOI: 10.1200/JCO.2017.35.15_SUPPL.1097 |
0.344 |
|
| 2017 |
Duan H, Reed R, Garber J, Pathania S. Abstract PR05: Distinct BRCA1- and BRCA2-specific functions at stalled replication forks: Clinical implications for differences between BRCA1 and BRCA2 mutation-driven cancer Molecular Cancer Research. 15. DOI: 10.1158/1557-3125.Dnarepair16-Pr05 |
0.425 |
|
| 2017 |
Telli M, Badve S, Vinayak S, Silver D, Isakoff S, Kaklamani V, Gradishar W, Stearns V, Connolly R, Ford J, Adams S, Garber J, Evans B, Timms K, Wenstrup R, et al. Abstract P6-09-09: Evaluation of tumor infiltrating lymphocytes (TILs) and their association with homologous recombination deficiency and BRCA1/2 mutation status in triple-negative breast cancer (TNBC): A pooled analysis Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P6-09-09 |
0.351 |
|
| 2017 |
Pathania S, Reed R, Duan H, Culhane A, Garber J. Abstract P5-06-04: Distinct BRCA1 and BRCA2 specific functions at stalled replication forks - Clinical implications for differences between BRCA1 and BRCA2 mutation driven cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P5-06-04 |
0.395 |
|
| 2017 |
Singhal H, Chi D, Lim E, He H, Vadhi R, Rao PK, Long HW, Richardson AL, Garber J, Brown M. Abstract LB-257: Estrogen signaling in mature luminal and luminal progenitor cells of BRCA2 carriers and non-carriers Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-257 |
0.436 |
|
| 2017 |
Maxwell KN, Slavin TP, Lilyquist JM, Vijai J, Neuhausen SL, Hart SN, Ravichandran V, Thomas T, Maria A, Schrader KA, Moore R, Hu C, Wubbenhorst B, Wenz BM, D'Andrea K, ... ... Garber JE, et al. Abstract 4265: Risks of familial breast cancer associated with known and proposed breast cancer susceptibility genes Epidemiology. 77: 4265-4265. DOI: 10.1158/1538-7445.Am2017-4265 |
0.464 |
|
| 2017 |
Chi D, Singhal H, Li L, Long HW, Garber JE, Brown MA. Abstract 3376: Reprogramming the estrogen signaling network is a potential mechanism for human breast tumorigenesis Cancer Research. 77: 3376-3376. DOI: 10.1158/1538-7445.Am2017-3376 |
0.406 |
|
| 2017 |
Tutt A, Kaufman B, Garber J, Gelber R, McFadden E, Goessl C, Viale G, Geyer C, Zardavas D, Arahmani A, Fumagalli D, Azambuja ED, Ponde N, Herbolsheimer P, Wu W, et al. 216TiPOlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm) Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx362.065 |
0.431 |
|
| 2017 |
Garber J. The risks and benefits of panel germline testing in breast cancer (BC) The Breast. 32: S6-S7. DOI: 10.1016/S0960-9776(17)30069-3 |
0.462 |
|
| 2016 |
Tung N, Garber JE, Hacker MR, Torous V, Freeman GJ, Poles E, Rodig S, Alexander B, Lee L, Collins LC, Schnitt SJ. Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer. Npj Breast Cancer. 2: 16002. PMID 28721372 DOI: 10.1038/npjbcancer.2016.2 |
0.412 |
|
| 2016 |
Hamdi Y, Soucy P, Kuchenbaeker KB, Pastinen T, Droit A, Lemaçon A, Adlard J, Aittomäki K, Andrulis IL, Arason A, Arnold N, Arun BK, Azzollini J, Bane A, Barjhoux L, ... ... Garber J, et al. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment. PMID 27796716 DOI: 10.1007/S10549-016-4018-2 |
0.487 |
|
| 2016 |
Isakoff SJ, Puhalla S, Domchek SM, Friedlander M, Kaufman B, Robson M, Telli ML, Diéras V, Han HS, Garber JE, Johnson EF, Maag D, Qin Q, Giranda VL, Shepherd SP. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology (London, England). PMID 27739325 DOI: 10.2217/fon-2016-0412 |
0.42 |
|
| 2016 |
Graffeo R, Livraghi L, Pagani O, Goldhirsch A, Partridge AH, Garber JE. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care. Breast Cancer Research and Treatment. PMID 27734215 DOI: 10.1007/s10549-016-4003-9 |
0.451 |
|
| 2016 |
Lawrenson K, Kar S, McCue K, Kuchenbaeker K, Michailidou K, Tyrer J, Beesley J, Ramus SJ, Li Q, Delgado MK, Lee JM, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, ... ... Garber J, et al. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nature Communications. 7: 12675. PMID 27601076 DOI: 10.1038/ncomms12675 |
0.338 |
|
| 2016 |
Vigorito E, Kuchenbaecker KB, Beesley J, Adlard J, Agnarsson BA, Andrulis IL, Arun BK, Barjhoux L, Belotti M, Benitez J, Berger A, Bojesen A, Bonanni B, Brewer C, Caldes T, ... ... Garber J, et al. Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Plos One. 11: e0158801. PMID 27463617 DOI: 10.1371/Journal.Pone.0158801 |
0.396 |
|
| 2016 |
Zeng C, Guo X, Long J, Kuchenbaecker KB, Droit A, Michailidou K, Ghoussaini M, Kar S, Freeman A, Hopper JL, Milne RL, Bolla MK, Wang Q, Dennis J, Agata S, ... ... Garber J, et al. Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research : Bcr. 18: 64. PMID 27459855 DOI: 10.1186/S13058-016-0718-0 |
0.346 |
|
| 2016 |
Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA, Nathanson KL, Konner JA, Arnold AG, Bogomolniy F, Dao F, Olvera N, Bancroft EK, Goldfrank DJ, Stadler ZK, ... ... Garber JE, et al. Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. Jama Oncology. PMID 27367496 DOI: 10.1001/Jamaoncol.2016.1820 |
0.377 |
|
| 2016 |
Tung N, Domchek SM, Stadler Z, Nathanson KL, Couch F, Garber JE, Offit K, Robson ME. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nature Reviews. Clinical Oncology. PMID 27296296 DOI: 10.1038/Nrclinonc.2016.90 |
0.366 |
|
| 2016 |
Malkin D, Garber JE, Strong LC, Friend SH. CANCER. The cancer predisposition revolution. Science (New York, N.Y.). 352: 1052-3. PMID 27230363 DOI: 10.1126/Science.Aag0832 |
0.384 |
|
| 2016 |
Couch FJ, Kuchenbaecker KB, Michailidou K, Mendoza-Fandino GA, Nord S, Lilyquist J, Olswold C, Hallberg E, Agata S, Ahsan H, Aittomäki K, Ambrosone C, Andrulis IL, Anton-Culver H, Arndt V, ... ... Garber J, et al. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications. 7: 11375. PMID 27117709 DOI: 10.1038/Ncomms11375 |
0.433 |
|
| 2016 |
Tung N, Lin NU, Kidd J, Allen BA, Singh N, Wenstrup RJ, Hartman AR, Winer EP, Garber JE. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26976419 DOI: 10.1200/JCO.2015.65.0747 |
0.5 |
|
| 2016 |
Telli ML, Timms KM, Reid JE, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung N, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, ... ... Garber JE, et al. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple Negative Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26957554 DOI: 10.1158/1078-0432.Ccr-15-2477 |
0.319 |
|
| 2016 |
YongLi J, Rounds T, Crocker AM, Sussman B, Hovey RC, Kingsley F, Muss H, Garber JE, Wood ME. The effect of atorvastatin on breast cancer biomarkers in high-risk women. Cancer Prevention Research (Philadelphia, Pa.). PMID 26908565 DOI: 10.1158/1940-6207.Capr-15-0300 |
0.405 |
|
| 2016 |
Rosenberg SM, Ruddy KJ, Tamimi RM, Gelber S, Schapira L, Come S, Borges VF, Larsen B, Garber JE, Partridge AH. BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer. Jama Oncology. PMID 26867710 DOI: 10.1001/jamaoncol.2015.5941 |
0.429 |
|
| 2016 |
Silvestri V, Barrowdale D, Mulligan AM, Neuhausen SL, Fox S, Karlan BY, Mitchell G, James P, Thull DL, Zorn KK, Carter NJ, Nathanson KL, Domchek SM, Rebbeck TR, Ramus SJ, ... ... Garber J, et al. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research : Bcr. 18: 15. PMID 26857456 DOI: 10.1186/S13058-016-0671-Y |
0.46 |
|
| 2016 |
Daly MB, Pilarski R, Axilbund JE, Berry M, Buys SS, Crawford B, Farmer M, Friedman S, Garber JE, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, et al. Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. Journal of the National Comprehensive Cancer Network : Jnccn. 14: 153-62. PMID 26850485 DOI: 10.6004/Jnccn.2016.0018 |
0.445 |
|
| 2016 |
Borgquist S, Tamimi RM, Chen WY, Garber JE, Eliassen AH, Ahern TP. Statin Use and Breast Cancer Risk in the Nurses' Health Study. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 25: 201-6. PMID 26762806 DOI: 10.1158/1055-9965.Epi-15-0654 |
0.434 |
|
| 2016 |
Kensler TW, Spira A, Garber JE, Szabo E, Lee JJ, Dong Z, Dannenberg AJ, Hait WN, Blackburn E, Davidson NE, Foti M, Lippman SM. Transforming Cancer Prevention through Precision Medicine and Immune-oncology. Cancer Prevention Research (Philadelphia, Pa.). 9: 2-10. PMID 26744449 DOI: 10.1158/1940-6207.Capr-15-0406 |
0.329 |
|
| 2016 |
Meeks HD, Song H, Michailidou K, Bolla MK, Dennis J, Wang Q, Barrowdale D, Frost D, McGuffog L, Ellis S, Feng B, Buys SS, Hopper JL, Southey MC, ... ... Garber J, et al. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute. 108. PMID 26586665 DOI: 10.1093/Jnci/Djv315 |
0.458 |
|
| 2016 |
Walsh MF, Gaddam P, Digiovanni L, Balmaña J, Dolinsky JS, Sittler T, Klein R, Lincoln SE, Allen B, Leighton J, Strom C, Ranger-Miller V, Brown K, Garber JE, Couch FJ, et al. Prospective registry of multiplex testing (PROMPT): A web-based platform to assess cancer risk of genetic variants. Journal of Clinical Oncology. 34: 1518-1518. DOI: 10.1200/JCO.2016.34.15_SUPPL.1518 |
0.319 |
|
| 2016 |
Tung NM, Garber JE, Hacker MR, Torous V, Nalven T, Alexander BM, Lee LJ, Collins LC, Schnitt SJ. Distant recurrences in triple negative breast cancer (TNBC) according to androgen receptor (AR) status. Journal of Clinical Oncology. 34: 1085-1085. DOI: 10.1200/JCO.2016.34.15_SUPPL.1085 |
0.372 |
|
| 2016 |
Borgquist S, Giobbie-Hurder A, Ahern T, Garber J, Colleoni M, Láng I, Debled M, Ejlertsen B, Coates A, Goldhirsch A, Price K, Gelber R, Regan M, Thürlimann B. Abstract PD1-03: Cholesterol, cholesterol lowering medication use, and breast cancer outcomes in the BIG 1-98 study Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-Pd1-03 |
0.312 |
|
| 2016 |
Ahern T, Tamimi R, Chen W, Garber J, Eliassen A, Borgquist S. Abstract PD1-02: Statin use and breast cancer incidence in the Nurses' health study Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-Pd1-02 |
0.424 |
|
| 2016 |
Garber J, Tung N, Elkin E, Allen B, Singh N, Wenstrup R, Hartman A, Winer E, Lin N. Abstract P1-08-07: Predisposing germline mutations in a clinic based breast cancer (BC) population Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P1-08-07 |
0.508 |
|
| 2016 |
Pathania S, Reed R, Duan H, Culhane A, Garber J. Abstract LB-162: BRCA2, and not BRCA1, dependent crosstalk between replication stress suppression and nucleotide excision repair - Clinical implications Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-162 |
0.371 |
|
| 2016 |
Balmaña J, Cruz C, Arun BK, Telli M, Garber J, Domchek S, Fernandez CM, Kahatt C, Szyldergemajn S, Soto-Matos A, Haza APdl, Fidalgo JAP, Lluch-Hernandez A, Antolin S, Tung NM, et al. Anti-tumor activity of PM01183 (lurbinectedin) in BRCA1/2-associated metastatic breast cancer patients: results of a single-agent phase II trial Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw365.02 |
0.342 |
|
| 2015 |
Ruddy KJ, Risendal BC, Garber JE, Partridge AH. Cancer Survivorship Care: An Opportunity to Revisit Cancer Genetics. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26712228 DOI: 10.1200/JCO.2015.63.5375 |
0.323 |
|
| 2015 |
Livraghi L, Garber JE. PARP inhibitors in the management of breast cancer: current data and future prospects. Bmc Medicine. 13: 188. PMID 26268938 DOI: 10.1186/s12916-015-0425-1 |
0.421 |
|
| 2015 |
McEvoy MP, Coopey SB, Mazzola E, Buckley J, Belli A, Polubriaginof F, Merrill AL, Tang R, Garber JE, Smith BL, Gadd MA, Specht MC, Guidi AJ, Roche CA, Hughes KS. Breast Cancer Risk and Follow-up Recommendations for Young Women Diagnosed with Atypical Hyperplasia and Lobular Carcinoma In Situ (LCIS). Annals of Surgical Oncology. 22: 3346-9. PMID 26242364 DOI: 10.1245/S10434-015-4747-1 |
0.418 |
|
| 2015 |
Bevers TB, Ward JH, Arun BK, Colditz GA, Cowan KH, Daly MB, Garber JE, Gemignani ML, Gradishar WJ, Jordan JA, Korde LA, Kounalakis N, Krontiras H, Kumar S, Kurian A, et al. Breast Cancer Risk Reduction, Version 2.2015. Journal of the National Comprehensive Cancer Network : Jnccn. 13: 880-915. PMID 26150582 DOI: 10.6004/Jnccn.2015.0105 |
0.474 |
|
| 2015 |
Hollestelle A, van der Baan FH, Berchuck A, Johnatty SE, Aben KK, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Anton-Culver H, Antonenkova NN, Antoniou AC, Apicella C, Arndt V, ... ... Garber J, et al. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology. PMID 25940428 DOI: 10.1016/J.Ygyno.2015.04.034 |
0.428 |
|
| 2015 |
Blein S, Bardel C, Danjean V, McGuffog L, Healey S, Barrowdale D, Lee A, Dennis J, Kuchenbaecker KB, Soucy P, Terry MB, Chung WK, Goldgar DE, Buys SS, ... ... Garber J, et al. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research : Bcr. 17: 61. PMID 25925750 DOI: 10.1186/S13058-015-0567-2 |
0.38 |
|
| 2015 |
Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL, Laitman Y, Kushnir A, Paluch-Shimon S, ... ... Garber J, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. Jama. 313: 1347-61. PMID 25849179 DOI: 10.1001/Jama.2014.5985 |
0.474 |
|
| 2015 |
Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, et al. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1902-9. PMID 25847936 DOI: 10.1200/Jco.2014.57.6660 |
0.321 |
|
| 2015 |
Blanco I, Kuchenbaecker K, Cuadras D, Wang X, Barrowdale D, de Garibay GR, Librado P, Sánchez-Gracia A, Rozas J, Bonifaci N, McGuffog L, Pankratz VS, Islam A, Mateo F, Berenguer A, ... ... Garber J, et al. Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. Plos One. 10: e0120020. PMID 25830658 DOI: 10.1371/Journal.Pone.0120020 |
0.442 |
|
| 2015 |
Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson K, McGuffog L, Healey S, Lee JM, Spindler TJ, Lin YG, Pejovic T, Bean Y, Li Q, ... ... Garber J, et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics. 47: 164-71. PMID 25581431 DOI: 10.1038/ng.3185 |
0.37 |
|
| 2015 |
Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, Olson JE, Godwin AK, Pankratz VS, Olswold C, Slettedahl S, Hallberg E, Guidugli L, Davila JI, Beckmann MW, ... ... Garber J, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 304-11. PMID 25452441 DOI: 10.1200/Jco.2014.57.1414 |
0.505 |
|
| 2015 |
Peterlongo P, Chang-Claude J, Moysich KB, Rudolph A, Schmutzler RK, Simard J, Soucy P, Eeles RA, Easton DF, Hamann U, Wilkening S, Chen B, Rookus MA, Schmidt MK, van der Baan FH, ... ... Garber JE, et al. Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 24: 308-16. PMID 25336561 DOI: 10.1158/1055-9965.Epi-14-0532 |
0.476 |
|
| 2015 |
Butrick M, Kelly S, Peshkin BN, Luta G, Nusbaum R, Hooker GW, Graves K, Feeley L, Isaacs C, Valdimarsdottir HB, Jandorf L, DeMarco T, Wood M, McKinnon W, Garber J, et al. Disparities in uptake of BRCA1/2 genetic testing in a randomized trial of telephone counseling. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 17: 467-75. PMID 25232856 DOI: 10.1038/gim.2014.125 |
0.324 |
|
| 2015 |
Tung N, Battelli C, Allen B, Kaldate R, Bhatnagar S, Bowles K, Timms K, Garber JE, Herold C, Ellisen L, Krejdovsky J, DeLeonardis K, Sedgwick K, Soltis K, Roa B, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer. 121: 25-33. PMID 25186627 DOI: 10.1002/cncr.29010 |
0.433 |
|
| 2015 |
O'Neill SC, Mays D, Patenaude AF, Garber JE, DeMarco TA, Peshkin BN, Schneider KA, Tercyak KP. Women's concerns about the emotional impact of awareness of heritable breast cancer risk and its implications for their children. Journal of Community Genetics. 6: 55-62. PMID 25099078 DOI: 10.1007/S12687-014-0201-5 |
0.354 |
|
| 2015 |
Tong A, Kelly S, Nusbaum R, Graves K, Peshkin BN, Valdimarsdottir HB, Wood M, McKinnon W, Garber J, McCormick SR, Jandorf L, Schwartz MD. Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling. Psycho-Oncology. 24: 33-9. PMID 24839250 DOI: 10.1002/Pon.3560 |
0.313 |
|
| 2015 |
Tutt ANJ, Kaufman B, Gelber RD, Mc Fadden E, Goessl CD, Viale G, Arahmani A, Fumagalli D, Azim HA, Wu W, Grocholewicz A, Costantino JP, Rastogi P, Garber JE, Geyer CE. OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm). Journal of Clinical Oncology. 33: TPS1109-TPS1109. DOI: 10.1200/JCO.2015.33.15_SUPPL.TPS1109 |
0.431 |
|
| 2015 |
Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA, Robson ME, Konner JA, Blum JL, Neuhausen SL, Garber JE, Daly MB, Isaacs C, Eeles RA, Ganz PA, et al. Uterine cancer (Ut Ca) following risk-reducing salpingo-oophorectomy (RRSO) in women with BRCA mutations (BRCA+): A multicenter, prospective study. Journal of Clinical Oncology. 33: 1504-1504. DOI: 10.1200/Jco.2015.33.15_Suppl.1504 |
0.306 |
|
| 2015 |
Garber JE, Tung NM, Elkin EP, Allen B, Hartman A, Singh N, Wenstrup RJ, Winer EP, Lin NU. Predisposing germline mutations in high grade ER+HER2- breast cancer (BC) patients diagnosed (Dx). Journal of Clinical Oncology. 33: 1503-1503. DOI: 10.1200/JCO.2015.33.15_SUPPL.1503 |
0.456 |
|
| 2015 |
Howitt BE, Hanamornroongruang S, Lin D, Conner JE, Schulte S, Garber J, Crum CP, Meserve EE. Abstract POSTER-CTRL-1208: A dualistic model for the origin of high-grade serous carcinoma: BRCA mutation status, histology and tubal intraepithelial carcinoma Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Ctrl-1208 |
0.317 |
|
| 2015 |
Pathania S, Bade S, Guillou ML, Burke K, Su Y, Ting DT, Polyak K, Richardson AL, Feunteun J, Garber JE, Livingston DM. Abstract S5-05: Defective stalled replication fork repair and predisposition to hereditary breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-S5-05 |
0.456 |
|
| 2015 |
Couch FJ, Hart SN, Sharma P, Toland AE, Miron P, Olson JE, Godwin A, Pankratz VS, Olswold C, Slettedahl S, Guidugli L, Beckmann MW, Rack B, Ekici AB, Konstantopoulou I, ... ... Garber J, et al. Abstract P4-12-03: Triple-negative breast cancer: Frequency of inherited mutations in breast cancer susceptibility genes Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P4-12-03 |
0.504 |
|
| 2015 |
Balmaña J, Cruz C, Garber J, Fidalgo JAP, Lluch A, Tung N, Antolin S, Fernandez C, Kahatt C, Szyldergemajn S, Matos AS, Extremera S, Baselga J, Isakoff SJ. Abstract P3-13-01: Lurbinectedin (PM01183) activity in BRCA1/2-associated or unselected metastatic breast cancer. Interim results of an ongoing phase II trial Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-13-01 |
0.353 |
|
| 2015 |
Richardson AL, Silver DP, Szallasi Z, Birkbak NJ, Wang ZC, Iglehart JD, Mayer EL, Winer EP, Tung NM, Ryan PD, Isakoff SJ, Barry WT, Greene-Collozi A, Gutin A, Reid J, ... ... Garber JE, et al. Abstract P3-06-11: Homologous recombination deficiency (HRD) assay predicts response to cisplatin neoadjuvant chemotherapy in patients with triple negative breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-06-11 |
0.382 |
|
| 2015 |
Robson M, Tutt A, Balmaña J, Kaufman B, Garber J, Geyer C, Ford J, Sharma P, Stuart M, Mann H, Fasching PA. Abstract OT1-1-04: OlympiA, Neo-Olympia and OlympiAD: Randomized phase III trials of olaparib in patients (pts) with breast cancer (BC) and a germlineBRCA1/2mutation (gBRCAm): Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-Ot1-1-04 |
0.308 |
|
| 2015 |
Garber J. PG 6.01 Using germline genetics in the management of breast cancer patients and their families The Breast. 24: S10-S11. DOI: 10.1016/S0960-9776(15)70023-8 |
0.402 |
|
| 2014 |
Kuchenbaecker KB, Neuhausen SL, Robson M, Barrowdale D, McGuffog L, Mulligan AM, Andrulis IL, Spurdle AB, Schmidt MK, Schmutzler RK, Engel C, Wappenschmidt B, Nevanlinna H, Thomassen M, Southey M, ... ... Garber J, et al. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research : Bcr. 16: 3416. PMID 25919761 DOI: 10.1186/S13058-014-0492-9 |
0.367 |
|
| 2014 |
Spurdle AB, Couch FJ, Parsons MT, McGuffog L, Barrowdale D, Bolla MK, Wang Q, Healey S, Schmutzler R, Wappenschmidt B, Rhiem K, Hahnen E, Engel C, Meindl A, Ditsch N, ... ... Garber J, et al. Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Research : Bcr. 16: 3419. PMID 25857409 DOI: 10.1186/S13058-014-0474-Y |
0.377 |
|
| 2014 |
Pathania S, Bade S, Le Guillou M, Burke K, Reed R, Bowman-Colin C, Su Y, Ting DT, Polyak K, Richardson AL, Feunteun J, Garber JE, Livingston DM. BRCA1 haploinsufficiency for replication stress suppression in primary cells. Nature Communications. 5: 5496. PMID 25400221 DOI: 10.1038/Ncomms6496 |
0.326 |
|
| 2014 |
Chai X, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Tung N, Weitzel JN, Couch FJ, Hulick PJ, Ganz PA, et al. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment. 148: 397-406. PMID 25311111 DOI: 10.1007/S10549-014-3134-0 |
0.442 |
|
| 2014 |
Daly MB, Pilarski R, Axilbund JE, Buys SS, Crawford B, Friedman S, Garber JE, Horton C, Kaklamani V, Klein C, Kohlmann W, Kurian A, Litton J, Madlensky L, Marcom PK, et al. Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. Journal of the National Comprehensive Cancer Network : Jnccn. 12: 1326-38. PMID 25190698 DOI: 10.6004/Jnccn.2014.0127 |
0.419 |
|
| 2014 |
Tung N, Gaughan E, Hacker MR, Lee LJ, Alexander B, Poles E, Schnitt SJ, Garber JE. Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers. Breast Cancer Research and Treatment. 146: 175-82. PMID 24839033 DOI: 10.1007/s10549-014-2995-6 |
0.457 |
|
| 2014 |
Kamihara J, Rana HQ, Garber JE. Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome. Human Mutation. 35: 654-62. PMID 24706533 DOI: 10.1002/humu.22559 |
0.367 |
|
| 2014 |
Osorio A, Milne RL, Kuchenbaecker K, Vaclová T, Pita G, Alonso R, Peterlongo P, Blanco I, de la Hoya M, Duran M, DÃez O, Ramón Y Cajal T, Konstantopoulou I, MartÃnez-Bouzas C, Andrés Conejero R, ... ... Garber J, et al. DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. Plos Genetics. 10: e1004256. PMID 24698998 DOI: 10.1371/Journal.Pgen.1004256 |
0.422 |
|
| 2014 |
Jackson SA, Davis AA, Li J, Yi N, McCormick SR, Grant C, Fallen T, Crawford B, Loranger K, Litton J, Arun B, Vande Wydeven K, Sidani A, Farmer K, Sanders M, ... ... Garber JE, et al. Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2. Cancer. 120: 1557-64. PMID 24522996 DOI: 10.1002/Cncr.28577 |
0.462 |
|
| 2014 |
Conner JR, Meserve E, Pizer E, Garber J, Roh M, Urban N, Drescher C, Quade BJ, Muto M, Howitt BE, Pearlman MD, Berkowitz RS, Horowitz N, Crum CP, Feltmate C. Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. Gynecologic Oncology. 132: 280-6. PMID 24333842 DOI: 10.1016/J.Ygyno.2013.12.009 |
0.313 |
|
| 2014 |
Gucalp A, Morris PG, Zhou XK, Giri DD, Iyengar NM, Crew KD, Hershman DL, Garber JE, Nangia JR, Cook ED, Vornik L, Dunn BK, Heckman-Stoddard BM, Foster K, Brown P, et al. A multicenter phase II study of docosahexaenoic acid (DHA) in patients (pts) with a history of breast cancer (BC), premalignant lesions, or benign breast disease. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps1615 |
0.339 |
|
| 2014 |
Rosenberg SM, Ruddy KJ, Tamimi RM, Gelber SI, Schapira L, Come SE, Borges VF, Larsen BG, Garber JE, Partridge AH. BRCA1/BRCA2 (BRCA) testing in young women with breast cancer: Patterns, motivations, and implications for treatment decisions. Journal of Clinical Oncology. 32: 6548-6548. DOI: 10.1200/JCO.2014.32.15_SUPPL.6548 |
0.408 |
|
| 2014 |
Rosenberg S, Ruddy K, Tamimi R, Gelber S, Schapira L, Come S, Borges V, Larsen B, Garber J, Partridge A. PO18 BRCA1/BRCA2 (BRCA) testing in young women with breast cancer: patterns; motivations and implications for treatment decisions The Breast. 23. DOI: 10.1016/S0960-9776(14)70028-1 |
0.407 |
|
| 2013 |
Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, Davidson NE, Decensi A, Fabian C, Ford L, Garber J, Katapodi M, Kramer B, Morrow M, Parker B, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 2942-62. PMID 23835710 DOI: 10.1200/Jco.2013.49.3122 |
0.353 |
|
| 2013 |
Choudhury S, Almendro V, Merino VF, Wu Z, Maruyama R, Su Y, Martins FC, Fackler MJ, Bessarabova M, Kowalczyk A, Conway T, Beresford-Smith B, Macintyre G, Cheng YK, Lopez-Bujanda Z, ... ... Garber JE, et al. Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics. Cell Stem Cell. 13: 117-30. PMID 23770079 DOI: 10.1016/J.Stem.2013.05.004 |
0.4 |
|
| 2013 |
Ng AK, Garber JE, Diller LR, Birdwell RL, Feng Y, Neuberg DS, Silver B, Fisher DC, Marcus KJ, Mauch PM. Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 2282-8. PMID 23610104 DOI: 10.1200/JCO.2012.46.5732 |
0.364 |
|
| 2013 |
Rath MG, Masciari S, Gelman R, Miron A, Miron P, Foley K, Richardson AL, Krop IE, Verselis SJ, Dillon DA, Garber JE. Prevalence of germline TP53 mutations in HER2+ breast cancer patients. Breast Cancer Research and Treatment. 139: 193-8. PMID 23580068 DOI: 10.1007/s10549-012-2375-z |
0.498 |
|
| 2013 |
Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy P, Fredericksen Z, Barrowdale D, Dennis J, Gaudet MM, Dicks E, Kosel M, Healey S, Sinilnikova OM, ... ... Garber J, et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. Plos Genetics. 9: e1003212. PMID 23544013 DOI: 10.1371/Journal.Pgen.1003212 |
0.447 |
|
| 2013 |
Gaudet MM, Kuchenbaecker KB, Vijai J, Klein RJ, Kirchhoff T, McGuffog L, Barrowdale D, Dunning AM, Lee A, Dennis J, Healey S, Dicks E, Soucy P, Sinilnikova OM, Pankratz VS, ... ... Garber J, et al. Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. Plos Genetics. 9: e1003173. PMID 23544012 DOI: 10.1371/Journal.Pgen.1003173 |
0.502 |
|
| 2013 |
Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, Edwards SL, Pickett HA, Shen HC, Smart CE, Hillman KM, Mai PL, Lawrenson K, Stutz MD, Lu Y, ... ... Garber J, et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics. 45: 371-84, 384e1-2. PMID 23535731 DOI: 10.1038/Ng.2566 |
0.349 |
|
| 2013 |
Domchek SM, Bradbury A, Garber JE, Offit K, Robson ME. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 1267-70. PMID 23460708 DOI: 10.1200/JCO.2012.46.9403 |
0.304 |
|
| 2013 |
Patenaude AF, Tung N, Ryan PD, Ellisen LW, Hewitt L, Schneider KA, Tercyak KP, Aldridge J, Garber JE. Young adult daughters of BRCA1/2 positive mothers: what do they know about hereditary cancer and how much do they worry? Psycho-Oncology. 22: 2024-31. PMID 23417902 DOI: 10.1002/pon.3257 |
0.34 |
|
| 2013 |
Oxnard GR, Heng JC, Rainville IR, Dahlberg SE, Sable-Hunt AL, Wiesner GL, Taylor KA, Jackman DM, Janne PA, Garber JE. Investigating hereditary risk from T790M (inherit): A prospective multicentered study of risk associated with germ-line EGFR T790M. Journal of Clinical Oncology. 31: TPS1606-TPS1606. DOI: 10.1200/JCO.2013.31.15_SUPPL.TPS1606 |
0.344 |
|
| 2013 |
O'Neill AF, Steinberger A, Voss SD, Root EJ, Garber JE, Diller L. Screening with whole-body MRI (WB-MRI) in pediatric patients with Li Fraumeni syndrome (LFS). Journal of Clinical Oncology. 31: 10071-10071. DOI: 10.1200/JCO.2013.31.15_SUPPL.10071 |
0.325 |
|
| 2013 |
Allen EMV, Wagle N, Keizun A, Kryukov G, McKenna A, Huang F, Hiller E, Rainville I, Auclair D, Ambrogio L, Gray S, Joffe S, Getz G, Garber J, Garraway L. Abstract 2570: An integrated germline analysis platform for comprehensive clinical cancer genomics. Cancer Research. 73: 2570-2570. DOI: 10.1158/1538-7445.Am2013-2570 |
0.318 |
|
| 2013 |
Chi D, He H, Yeung T, Jeselsohn R, Schnitt S, Garber J, Richardson A, Lim E, Brown M. Abstract 2313: Differences in estrogen receptor signaling in normal mammary epithelial cells and ER-positive primary breast tumors and metastases. Cancer Research. 73: 2313-2313. DOI: 10.1158/1538-7445.Am2013-2313 |
0.398 |
|
| 2013 |
Isakoff S, Cruz C, Garber J, LLuch A, Fidalgo JP, Tung N, Fernandez C, Kahatt C, Szyldergemajn S, Matos-Pita AS, Baselga J, Balmaña J. Abstract OT1-4-01: Multicenter phase II trial of the novel compound PM01183 (P) in BRCA1/2-associated or unselected metastatic breast cancer (MBC) Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-Ot1-4-01 |
0.331 |
|
| 2012 |
Coopey SB, Mazzola E, Buckley JM, Sharko J, Belli AK, Kim EM, Polubriaginof F, Parmigiani G, Garber JE, Smith BL, Gadd MA, Specht MC, Guidi AJ, Roche CA, Hughes KS. The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast Cancer Research and Treatment. 136: 627-33. PMID 23117858 DOI: 10.1007/S10549-012-2318-8 |
0.459 |
|
| 2012 |
Tung N, Garber JE, Lincoln A, Domchek SM. Frequency of triple-negative breast cancer in BRCA1 mutation carriers: comparison between common Ashkenazi Jewish and other mutations. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 4447-8. PMID 23091104 DOI: 10.1200/JCO.2012.44.5635 |
0.415 |
|
| 2012 |
Yurgelun MB, Mercado R, Rosenblatt M, Dandapani M, Kohlmann W, Conrad P, Blanco A, Shannon KM, Chung DC, Terdiman J, Gruber SB, Garber JE, Syngal S, Stoffel EM. Impact of genetic testing on endometrial cancer risk-reducing practices in women at risk for Lynch syndrome. Gynecologic Oncology. 127: 544-51. PMID 22940489 DOI: 10.1016/J.Ygyno.2012.08.031 |
0.302 |
|
| 2012 |
Ding YC, McGuffog L, Healey S, Friedman E, Laitman Y, Paluch-Shimon S, Kaufman B, Liljegren A, Lindblom A, Olsson H, Kristoffersson U, Stenmark-Askmalm M, Melin B, Domchek SM, ... ... Garber JE, et al. A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 21: 1362-70. PMID 22729394 DOI: 10.1158/1055-9965.Epi-12-0229 |
0.469 |
|
| 2012 |
Martins FC, De S, Almendro V, Gönen M, Park SY, Blum JL, Herlihy W, Ethington G, Schnitt SJ, Tung N, Garber JE, Fetten K, Michor F, Polyak K. Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discovery. 2: 503-11. PMID 22628410 DOI: 10.1158/2159-8290.Cd-11-0325 |
0.375 |
|
| 2012 |
Kaplan JS, Schnitt SJ, Collins LC, Wang Y, Garber JE, Montgomery K, West RB, Krag K, Fetten K, Lincoln A, Tung NM. Pathologic features and immunophenotype of estrogen receptor-positive breast cancers in BRCA1 mutation carriers. The American Journal of Surgical Pathology. 36: 1483-8. PMID 22613997 DOI: 10.1097/PAS.0b013e31825789ed |
0.414 |
|
| 2012 |
Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, Jones D, Hinton J, Marshall J, Stebbings LA, Menzies A, Martin S, Leung K, Chen L, Leroy C, ... ... Garber JE, et al. Mutational processes molding the genomes of 21 breast cancers. Cell. 149: 979-93. PMID 22608084 DOI: 10.1016/j.cell.2012.04.024 |
0.403 |
|
| 2012 |
Finkelman BS, Rubinstein WS, Friedman S, Friebel TM, Dubitsky S, Schonberger NS, Shoretz R, Singer CF, Blum JL, Tung N, Olopade OI, Weitzel JN, Lynch HT, Snyder C, Garber JE, et al. Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 1321-8. PMID 22430266 DOI: 10.1200/Jco.2011.37.8133 |
0.478 |
|
| 2012 |
Liu J, Cristea MC, Frankel P, Neuhausen SL, Steele L, Engelstaedter V, Matulonis U, Sand S, Tung N, Garber JE, Weitzel JN. Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival. Cancer Genetics. 205: 34-41. PMID 22429596 DOI: 10.1016/j.cancergen.2012.01.008 |
0.311 |
|
| 2012 |
Masciari S, Dillon DA, Rath M, Robson M, Weitzel JN, Balmana J, Gruber SB, Ford JM, Euhus D, Lebensohn A, Telli M, Pochebit SM, Lypas G, Garber JE. Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Research and Treatment. 133: 1125-30. PMID 22392042 DOI: 10.1007/S10549-012-1993-9 |
0.467 |
|
| 2012 |
Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Spurdle A, Robson M, Sherman M, Mulligan AM, Couch FJ, Engel C, McGuffog L, Healey S, ... ... Garber JE, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 21: 134-47. PMID 22144499 DOI: 10.1158/1055-9965.Epi-11-0775 |
0.424 |
|
| 2012 |
Higgins MJ, Prowell TM, Blackford AL, Byrne C, Khouri NF, Slater SA, Jeter SC, Armstrong DK, Davidson NE, Emens LA, Fetting JH, Powers PP, Wolff AC, Green H, Thibert JN, ... ... Garber JE, et al. A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. Breast Cancer Research and Treatment. 131: 915-24. PMID 22076478 DOI: 10.1007/s10549-011-1858-7 |
0.428 |
|
| 2012 |
Shah PD, Garber JE, Stopfer J, Powers J, Nathanson KL, Domchek SM. Sensitivity of clinical BRCA1 testing compared with linkage analysis. Journal of Clinical Oncology. 30: 1506-1506. DOI: 10.1200/Jco.2012.30.15_Suppl.1506 |
0.355 |
|
| 2012 |
Isakoff S, Goss P, Mayer E, Traina T, Carey L, Krag K, Liu M, Rugo H, Stearns V, Come S, Finkelstein D, Hartman A, Garber J, Ryan P, Winer E, et al. Abstract PD09-03: Impact of BRCA1/2 Mutation Status in TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple negative breast cancer. Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-Pd09-03 |
0.393 |
|
| 2012 |
Lim E, He H, Chi D, Yeung T, Schnitt S, Liu S, Garber J, Richardson A, Brown M. Abstract PD01-08: Differences in estrogen receptor signaling in non-malignant primary ER-positive breast epithelial cells and breast cancer. Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-Pd01-08 |
0.339 |
|
| 2011 |
Domchek SM, Friebel T, Neuhausen SL, Lynch HT, Singer CF, Eeles RA, Isaacs C, Tung NM, Ganz PA, Couch FJ, Weitzel JN, Olopade OI, Rubinstein WS, Tomlinson GE, Pichert GC, ... ... Garber JE, et al. Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1501. PMID 28023617 DOI: 10.1200/jco.2011.29.15_suppl.1501 |
0.458 |
|
| 2011 |
Masciari S, Dillon D, Dick MG, Robson ME, Weitzel JN, Ford JM, Balmaña J, Gruber SB, Euhus D, Garber JE. Breast cancer phenotype in women with TP53 germ-line mutations: An LFS consortium effort. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1519. PMID 28023605 DOI: 10.1200/Jco.2011.29.15_Suppl.1519 |
0.405 |
|
| 2011 |
Isakoff SJ, Goss PE, Mayer EL, Traina TA, Carey LA, Krag K, Rugo HS, Liu MC, Stearns V, Come SE, Borger DR, Quadrino CA, Finkelstein D, Garber JE, Ryan PD, et al. TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1025. PMID 28020734 DOI: 10.1200/Jco.2011.29.15_Suppl.1025 |
0.329 |
|
| 2011 |
Balmaña J, Domchek SM, Tutt A, Garber JE. Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. Cancer Discovery. 1: 29-34. PMID 22586318 DOI: 10.1158/2159-8274.CD-11-0048 |
0.363 |
|
| 2011 |
Domchek SM, Mitchell G, Lindeman GJ, Tung NM, Balmaña J, Isakoff SJ, Schmutzler R, Audeh MW, Loman N, Scott C, Friedlander M, Kaufman B, Garber JE, Tutt A, Robson ME. Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4224-6. PMID 21931031 DOI: 10.1200/JCO.2011.36.8134 |
0.413 |
|
| 2011 |
Rebbeck TR, Mitra N, Domchek SM, Wan F, Friebel TM, Tran TV, Singer CF, Tea MK, Blum JL, Tung N, Olopade OI, Weitzel JN, Lynch HT, Snyder CL, Garber JE, et al. Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Research. 71: 5792-805. PMID 21799032 DOI: 10.1158/0008-5472.Can-11-0773 |
0.45 |
|
| 2011 |
Neuhausen SL, Brummel S, Ding YC, Steele L, Nathanson KL, Domchek S, Rebbeck TR, Singer CF, Pfeiler G, Lynch HT, Garber JE, Couch F, Weitzel JN, Godwin A, Narod SA, et al. Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 20: 1690-702. PMID 21708937 DOI: 10.1158/1055-9965.Epi-10-1336 |
0.449 |
|
| 2011 |
Goss PE, Ingle JN, Alés-MartÃnez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, et al. Exemestane for breast-cancer prevention in postmenopausal women. The New England Journal of Medicine. 364: 2381-91. PMID 21639806 DOI: 10.1056/Nejmoa1103507 |
0.453 |
|
| 2011 |
Im KM, Kirchhoff T, Wang X, Green T, Chow CY, Vijai J, Korn J, Gaudet MM, Fredericksen Z, Shane Pankratz V, Guiducci C, Crenshaw A, McGuffog L, Kartsonaki C, Morrison J, ... ... Garber J, et al. Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Human Genetics. 130: 685-99. PMID 21597964 DOI: 10.1007/S00439-011-1003-Z |
0.325 |
|
| 2011 |
Dewanwala A, Chittenden A, Rosenblatt M, Mercado R, Garber JE, Syngal S, Stoffel EM. Attitudes toward childbearing and prenatal testing in individuals undergoing genetic testing for Lynch Syndrome Familial Cancer. 10: 549-556. PMID 21567236 DOI: 10.1007/s10689-011-9448-8 |
0.312 |
|
| 2011 |
Masciari S, Dewanwala A, Stoffel EM, Lauwers GY, Zheng H, Achatz MI, Riegert-Johnson D, Foretova L, Silva EM, Digianni L, Verselis SJ, Schneider K, Li FP, Fraumeni J, Garber JE, et al. Gastric cancer in individuals with Li-Fraumeni syndrome. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 13: 651-7. PMID 21552135 DOI: 10.1097/GIM.0b013e31821628b6 |
0.305 |
|
| 2011 |
Spurdle AB, Marquart L, McGuffog L, Healey S, Sinilnikova O, Wan F, Chen X, Beesley J, Singer CF, Dressler AC, Gschwantler-Kaulich D, Blum JL, Tung N, Weitzel J, Lynch H, ... Garber J, et al. Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 20: 1032-8. PMID 21393566 DOI: 10.1158/1055-9965.Epi-10-0909 |
0.509 |
|
| 2011 |
Hofstatter EW, Domchek SM, Miron A, Garber J, Wang M, Componeschi K, Boghossian L, Miron PL, Nathanson KL, Tung N. PALB2 mutations in familial breast and pancreatic cancer. Familial Cancer. 10: 225-31. PMID 21365267 DOI: 10.1007/S10689-011-9426-1 |
0.462 |
|
| 2011 |
Levy DE, Byfield SD, Comstock CB, Garber JE, Syngal S, Crown WH, Shields AE. Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 13: 349-55. PMID 21358336 DOI: 10.1097/Gim.0B013E3182091Ba4 |
0.39 |
|
| 2011 |
Lee LJ, Alexander B, Schnitt SJ, Comander A, Gallagher B, Garber JE, Tung N. Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. Cancer. 117: 3093-100. PMID 21264845 DOI: 10.1002/cncr.25911 |
0.473 |
|
| 2011 |
Issa JPJ, Garber JE. Time to think outside the (genetic) box Cancer Prevention Research. 4: 6-8. PMID 21205738 DOI: 10.1158/1940-6207.CAPR-10-0348 |
0.428 |
|
| 2011 |
Schrader KA, Masciari S, Boyd N, Salamanca C, Senz J, Saunders DN, Yorida E, Maines-Bandiera S, Kaurah P, Tung N, Robson ME, Ryan PD, Olopade OI, Domchek SM, Ford J, ... ... Garber JE, et al. Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. Journal of Medical Genetics. 48: 64-8. PMID 20921021 DOI: 10.1136/Jmg.2010.079814 |
0.505 |
|
| 2011 |
Golshan M, Garber JE, Gelman R, Tung N, Smith BL, Troyan S, Greenberg CC, Winer EP, Ryan P. Does neoadjuvant bevacizumab increase surgical complications in breast surgery? Annals of Surgical Oncology. 18: 733-7. PMID 20882415 DOI: 10.1245/s10434-010-1366-8 |
0.383 |
|
| 2011 |
Rosenblatt M, Dandapani M, Mercado R, Garber JE, Syngal S, Stoffel EM. Factors associated with genetic testing distress in patients tested for Lynch Syndrome or Hereditary Breast and Ovarian Cancer Syndrome Hereditary Cancer in Clinical Practice. 9: P33. DOI: 10.1186/1897-4287-9-S1-P33 |
0.356 |
|
| 2011 |
Coopey S, Mazzola E, Buckley J, Sharko J, Belli A, Kim E, Polufriaginof F, Parmigiani G, Garber J, Smith B, Gadd M, Specht M, Guidi A, Roche C, Hughes K. S4-4: Clarifying the Risk of Breast Cancer in Women with Atypical Breast Lesions. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-S4-4 |
0.461 |
|
| 2011 |
Isakoff S, Overmoyer B, Tung N, Gelman R, Habin K, Qian J, Giranda V, Shepherd S, Garber J, Ellisen L, Winer E, Goss P. P3-16-05: A Phase II Trial Expansion Cohort of the PARP Inhibitor Veliparib (ABT888) and Temozolomide in BRCA1/2 Associated Metastatic Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P3-16-05 |
0.314 |
|
| 2011 |
Wood M, Kingsley F, Ellerton J, Atkins J, Grubs S, Muss H, Garber J. P3-11-04: A Randomized Phase II Biomarker Study of Atorvastatin in Premenopausal Women at Increased Risk for Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P3-11-04 |
0.442 |
|
| 2011 |
Dick M, Masciari S, Miron A, Miron P, Foley K, Gelman R, Dillon D, Richardson A, Verselis S, Lypas G, Krop I, Garber J. P1-09-03: Prevalence of Germline TP53 Mutations in Young Women with HER2−Positive Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P1-09-03 |
0.367 |
|
| 2010 |
Alexander BM, Sprott K, Farrow DA, Wang X, D'Andrea AD, Schnitt SJ, Collins LC, Weaver DT, Garber JE. DNA repair protein biomarkers associated with time to recurrence in triple-negative breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5796-804. PMID 21138871 DOI: 10.1158/1078-0432.Ccr-10-0292 |
0.331 |
|
| 2010 |
Tung N, Miron A, Schnitt SJ, Gautam S, Fetten K, Kaplan J, Yassin Y, Buraimoh A, Kim JY, Szász AM, Tian R, Wang ZC, Collins LC, Brock J, Krag K, ... ... Garber JE, et al. Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers. Breast Cancer Research : Bcr. 12: R95. PMID 21080930 DOI: 10.1186/bcr2776 |
0.459 |
|
| 2010 |
Gaudet MM, Kirchhoff T, Green T, Vijai J, Korn JM, Guiducci C, Segrè AV, McGee K, McGuffog L, Kartsonaki C, Morrison J, Healey S, Sinilnikova OM, Stoppa-Lyonnet D, Mazoyer S, ... ... Garber J, et al. Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. Plos Genetics. 6: e1001183. PMID 21060860 DOI: 10.1371/Journal.Pgen.1001183 |
0.406 |
|
| 2010 |
Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Loftus L, Macdonald DJ, et al. Breast cancer risk reduction. Journal of the National Comprehensive Cancer Network : Jnccn. 8: 1112-46. PMID 20971838 DOI: 10.6004/Jnccn.2010.0083 |
0.45 |
|
| 2010 |
Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R, Sinilnikova OM, Healey S, Morrison J, Kartsonaki C, Lesnick T, Ghoussaini M, Barrowdale D, Peock S, Cook M, ... ... Garber J, et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nature Genetics. 42: 885-92. PMID 20852631 DOI: 10.1038/Ng.669 |
0.439 |
|
| 2010 |
Domchek SM, Friebel TM, Singer CF, Gareth Evans D, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van T'veer L, Tung N, Weitzel JN, Couch FJ, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality Jama - Journal of the American Medical Association. 304: 967-975. PMID 20810374 DOI: 10.1001/Jama.2010.1237 |
0.45 |
|
| 2010 |
Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 376: 235-44. PMID 20609467 DOI: 10.1016/S0140-6736(10)60892-6 |
0.439 |
|
| 2010 |
Garber JE, Halabi S, Tolaney SM, Kaplan E, Archer L, Atkins JN, Edge S, Shapiro CL, Dressler L, Paskett ED, Paskett EM, Kimmick G, Orcutt J, Scalzo A, Winer E, et al. Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. Journal of the National Cancer Institute. 102: 942-9. PMID 20554945 DOI: 10.1093/Jnci/Djq211 |
0.441 |
|
| 2010 |
Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD, Friedman S, Garber JE, Goorha S, Gruber SB, Hampel H, Kaklamani V, Kohlmann W, Kurian A, Litton J, Marcom PK, et al. Genetic/familial high-risk assessment: breast and ovarian. Journal of the National Comprehensive Cancer Network : Jnccn. 8: 562-94. PMID 20495085 DOI: 10.6004/Jnccn.2010.0043 |
0.349 |
|
| 2010 |
Pierce LJ, Phillips KA, Griffith KA, Buys S, Gaffney DK, Moran MS, Haffty BG, Ben-David M, Kaufman B, Garber JE, Merajver SD, Balmaña J, Meirovitz A, Domchek SM. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Research and Treatment. 121: 389-98. PMID 20411323 DOI: 10.1007/S10549-010-0894-Z |
0.486 |
|
| 2010 |
Moorman PG, Iversen ES, Marcom PK, Marks JR, Wang F, Lee E, Ursin G, Rebbeck TR, Domchek SM, Arun B, Susswein L, Isaacs C, Garber JE, Visvanathan K, et al. Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. Breast Cancer Research and Treatment. 124: 441-51. PMID 20309627 DOI: 10.1007/S10549-010-0842-Y |
0.471 |
|
| 2010 |
Domchek SM, Friebel TM, Garber JE, Isaacs C, Matloff E, Eeles R, Evans DG, Rubinstein W, Singer CF, Rubin S, Lynch HT, Daly MB, Weitzel J, Ganz PA, Pichert G, et al. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers Breast Cancer Research and Treatment. 124: 195-203. PMID 20180014 DOI: 10.1007/S10549-010-0799-X |
0.42 |
|
| 2010 |
Tung N, Wang Y, Collins LC, Kaplan J, Li H, Gelman R, Comander AH, Gallagher B, Fetten K, Krag K, Stoeckert KA, Legare RD, Sgroi D, Ryan PD, Garber JE, et al. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Research : Bcr. 12: R12. PMID 20149218 DOI: 10.1186/bcr2478 |
0.424 |
|
| 2010 |
Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, ... ... Garber JE, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1145-53. PMID 20100965 DOI: 10.1200/JCO.2009.22.4725 |
0.436 |
|
| 2010 |
Ozanne EM, Wittenberg E, Garber JE, Weeks JC. Breast cancer prevention: patient decision making and risk communication in the high risk setting. The Breast Journal. 16: 38-47. PMID 19889168 DOI: 10.1111/j.1524-4741.2009.00857.x |
0.344 |
|
| 2010 |
Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Research and Treatment. 119: 137-44. PMID 19728082 DOI: 10.1007/S10549-009-0507-X |
0.336 |
|
| 2010 |
Ruddy KJ, Gelber S, Shin J, Garber JE, Rosenberg R, Przypysny M, Partridge AH. Genetic testing in young women with breast cancer: results from a Web-based survey. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 21: 741-7. PMID 19713245 DOI: 10.1093/annonc/mdp355 |
0.411 |
|
| 2010 |
Demarco TA, Nusbaum RH, Peshkin BN, Patenaude AF, Schneider KA, Garber JE, Valdimarsdottir HB, Tercyak KP. Prevalence and correlates of mothers and fathers attending pretest cancer genetic counseling together. Patient Education and Counseling. 78: 29-33. PMID 19545972 DOI: 10.1016/j.pec.2009.05.013 |
0.418 |
|
| 2010 |
Gaudet MM, Kirchhoff T, Green T, Vijai J, Korn JM, Guiducci C, Segrè AV, McGee K, McGuffog L, Kartsonaki C, Morrison J, Healey S, Sinilnikova OM, Stoppa-Lyonnet D, Mazoyer S, ... ... Garber J, et al. Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer Plos Genetics. 6. DOI: 10.1371/Annotation/B28Cf02D-7196-4A16-8B36-6562A0B84F75 |
0.368 |
|
| 2010 |
Gaudet MM, Kirchhoff T, Green T, Vijai J, Korn JM, Guiducci C, Segrè AV, McGee K, McGuffog L, Kartsonaki C, Morrison J, Healey S, Sinilnikova OM, Stoppa-Lyonnet D, Mazoyer S, ... ... Garber J, et al. Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer Plos Genetics. 6. DOI: 10.1371/annotation/59ea8540-4e63-4f4a-a79e-f68765fdeac7 |
0.439 |
|
| 2010 |
Wood ME, Kingsley F, Ellerton JA, Atkins JN, Grubbs SS, Muss HB, Garber JE. A randomized trial of atorvastatin versus placebo in women at high risk for breast cancer. Journal of Clinical Oncology. 28: TPS141-TPS141. DOI: 10.1200/JCO.2010.28.15_SUPPL.TPS141 |
0.392 |
|
| 2010 |
Higgins MJ, Prowell TM, Blackford A, Slater S, Argani P, Green H, Khouri N, Blumenthal R, Garber JE, Stearns V. A short-term biomarker modulation prevention study of simvastatin in women at increased risk for breast cancer. Journal of Clinical Oncology. 28: 1505-1505. DOI: 10.1200/JCO.2010.28.15_SUPPL.1505 |
0.4 |
|
| 2010 |
Dandapani M, Rosenblatt M, Chittenden A, Mercado R, Garber JE, Syngal S, Stoffel EM. Impact of mismatch repair (MMR) genetic test result on perceived cancer risk and cancer screening Hereditary Cancer in Clinical Practice. 8: P6. DOI: 10.1186/1897-4287-8-S1-P6 |
0.362 |
|
| 2010 |
Yurgelun MB, Mercado R, Rosenblatt M, Garber JE, Syngal S, Stoffel EM. Impact of genetic testing on risk-reducing behavior in women at risk for hereditary gynecologic cancer syndromes Hereditary Cancer in Clinical Practice. 8: P23. DOI: 10.1186/1897-4287-8-S1-P23 |
0.305 |
|
| 2010 |
Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J, et al. The future is 'PARP' - Phase-II-activity of PARP inhibitor among patients with BRCA-deficient breast cancer Breast Care. 5: 364-365. DOI: 10.1159/000322170 |
0.367 |
|
| 2010 |
Seewaldt VL, Ibarra C, Yee LD, Wilke LG, Kulkarni S, Wood M, Garber J, Ford A. Abstract A20: Random periareolar fine‐needle aspiration is highly reproducible in a CALGB multi‐institutional cross‐sectional study Cancer Prevention Research. 3. DOI: 10.1158/1940-6207.Prev-09-A20 |
0.456 |
|
| 2010 |
Pierce L, Phillips K, Griffith K, Buys S, Gaffney D, Moran M, Haffty B, Ben-David M, Garber J, Merajver S, Balmaña J, Meirovitz A, Domchek S. 7N Local therapy options in BRCA1/2 carriers with operable breast cancer: the importance of adjuvant chemotherapy European Journal of Cancer Supplements. 8: 55. DOI: 10.1016/S1359-6349(10)70034-3 |
0.362 |
|
| 2009 |
Comander AH, Gallagher BM, Krag K, Wang Y, Li H, Gelman R, Collins LC, Schnitt SJ, Garber JE, Tung N. Determination of factors predicting for estrogen receptor positive (ER+) breast cancers in BRCA1 mutation carriers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 11045. PMID 27963985 DOI: 10.1200/jco.2009.27.15_suppl.11045 |
0.413 |
|
| 2009 |
Masciari S, Schrader KA, Senz J, Tung N, Balmana J, Razzak AR, Miron P, Huntsman DG, Garber JE. Prevalence of CDH1 germline mutations in subjects with early onset or familial lobular breast cancer, a multicenter collaboration. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 11042. PMID 27963984 DOI: 10.1200/jco.2009.27.15_suppl.11042 |
0.444 |
|
| 2009 |
Ryan PD, Tung NM, Isakoff SJ, Golshan M, Richardson A, Corben AD, Smith BL, Gelman R, Winer EP, Garber JE. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 551. PMID 27960664 DOI: 10.1200/jco.2009.27.15_suppl.551 |
0.35 |
|
| 2009 |
Bevers TB, Anderson BO, Bonaccio E, Buys S, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE, Heerdt AS, Helvie M, Huff JG, Khakpour N, et al. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. Journal of the National Comprehensive Cancer Network : Jnccn. 7: 1060-96. PMID 19930975 DOI: 10.6004/Jnccn.2009.0070 |
0.353 |
|
| 2009 |
Garber JE, Golshan M. Contralateral breast cancer in BRCA1/BRCA2 mutation carriers: the story of the other side. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5862-4. PMID 19858367 DOI: 10.1200/JCO.2009.25.1652 |
0.475 |
|
| 2009 |
Neuhausen SL, Brummel S, Ding YC, Singer CF, Pfeiler G, Lynch HT, Nathanson KL, Rebbeck TR, Garber JE, Couch F, Weitzel J, Narod SA, Ganz PA, Daly MB, Godwin AK, et al. Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. Breast Cancer Research : Bcr. 11: R76. PMID 19843326 DOI: 10.1186/Bcr2414 |
0.455 |
|
| 2009 |
Zhang J, Song YH, Brannigan BW, Wahrer DC, Schiripo TA, Harris PL, Haserlat SM, Ulkus LE, Shannon KM, Garber JE, Freedman ML, Henderson BE, Zou L, Sgroi DC, Haber DA, et al. Prevalence and functional analysis of sequence variants in the ATR checkpoint mediator Claspin. Molecular Cancer Research : McR. 7: 1510-6. PMID 19737971 DOI: 10.1158/1541-7786.Mcr-09-0033 |
0.424 |
|
| 2009 |
De Nicolo A, Parisini E, Zhong Q, Dalla Palma M, Stoeckert KA, Domchek SM, Nathanson KL, Caligo MA, Vidal M, Cusick ME, Garber JE. Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688del. Cancer Research. 69: 7030-7. PMID 19706752 DOI: 10.1158/0008-5472.Can-09-1440 |
0.365 |
|
| 2009 |
Folkins AK, Saleemuddin A, Garrett LA, Garber JE, Muto MG, Tworoger SS, Crum CP. Epidemiologic correlates of ovarian cortical inclusion cysts (CICs) support a dual precursor pathway to pelvic epithelial cancer. Gynecologic Oncology. 115: 108-11. PMID 19615727 DOI: 10.1016/j.ygyno.2009.06.032 |
0.313 |
|
| 2009 |
Rebbeck TR, Mitra N, Domchek SM, Wan F, Chuai S, Friebel TM, Panossian S, Spurdle A, Chenevix-Trench G, Singer CF, Pfeiler G, Neuhausen SL, Lynch HT, Garber JE, et al. Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. Cancer Research. 69: 5801-10. PMID 19584272 DOI: 10.1158/0008-5472.Can-09-0625 |
0.419 |
|
| 2009 |
Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, et al. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3235-58. PMID 19470930 DOI: 10.1200/Jco.2008.20.5179 |
0.31 |
|
| 2009 |
Levy DE, Garber JE, Shields AE. Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilization. Journal of General Internal Medicine. 24: 822-8. PMID 19455369 DOI: 10.1007/S11606-009-1009-6 |
0.414 |
|
| 2009 |
Collins LC, Martyniak A, Kandel MJ, Stadler ZK, Masciari S, Miron A, Richardson AL, Schnitt SJ, Garber JE. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers American Journal of Surgical Pathology. 33: 1093-1097. PMID 19390427 DOI: 10.1097/PAS.0b013e31819c1c93 |
0.429 |
|
| 2009 |
Ibarra-Drendall C, Wilke LG, Zalles C, Scott V, Archer LE, Lem S, Yee LD, Lester J, Kulkarni S, Murekeyisoni C, Wood M, Wilson K, Garber J, Gentry C, Stouder A, et al. Reproducibility of random periareolar fine needle aspiration in a multi-institutional Cancer and Leukemia Group B (CALGB) cross-sectional study. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 18: 1379-85. PMID 19383884 DOI: 10.1158/1055-9965.Epi-08-1210 |
0.397 |
|
| 2009 |
Garber JE. BRCA1/2-associated and sporadic breast cancers: fellow travelers or not? Cancer Prevention Research (Philadelphia, Pa.). 2: 100-3. PMID 19174575 DOI: 10.1158/1940-6207.CAPR-08-0243 |
0.456 |
|
| 2009 |
Peshkin BN, DeMarco TA, Garber JE, Valdimarsdottir HB, Patenaude AF, Schneider KA, Schwartz MD, Tercyak KP. Brief assessment of parents' attitudes toward testing minor children for hereditary breast/ovarian cancer genes: development and validation of the Pediatric BRCA1/2 Testing Attitudes Scale (P-TAS). Journal of Pediatric Psychology. 34: 627-38. PMID 18385162 DOI: 10.1093/jpepsy/jsn033 |
0.342 |
|
| 2009 |
Tutt A, Robson M, Garber JE, Domchek S, Audeh MW, Weitzel JN, Friedlander M, Carmichael J. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer Journal of Clinical Oncology. 27: CRA501-CRA501. DOI: 10.1200/JCO.2009.27.18_SUPPL.CRA501 |
0.35 |
|
| 2009 |
Garwood E, Kumar A, Baehner F, Garber J, Troyan S, Olopade O, Moore D, Au A, Flowers C, Campbell M, Hylton N, Esserman L, Rush-Port E. Fluvastatin has biologic effects on stage 0 and 1 breast cancer. Cancer Research. 69: 4122. DOI: 10.1158/0008-5472.Sabcs-4122 |
0.328 |
|
| 2009 |
Wang Y, Collins L, Schnitt S, Garber J, Tung N. Characterization of estrogen receptor-positive breast cancers inBRCA1mutation carriers. Cancer Research. 69: 1105. DOI: 10.1158/0008-5472.Sabcs-1105 |
0.406 |
|
| 2009 |
Stadler Z, Stoeckert K, Perez A, Regan M, Golshan M, Garber J. Factors affecting surgical decision-making in patients undergoingBRCA1/2testing at breast cancer diagnosis. Cancer Research. 69: 1095. DOI: 10.1158/0008-5472.Sabcs-1095 |
0.349 |
|
| 2009 |
Alexander B, Sprott K, Wang X, D'Andrea A, Schnitt S, Collins L, Weaver D, Garber J. DNA repair protein biomarkers in triple negative breast cancer. Cancer Research. 69: 1064. DOI: 10.1158/0008-5472.Sabcs-1064 |
0.354 |
|
| 2009 |
Pierce L, Phillips K, Griffith K, Buys S, Gaffney D, Moran M, Haffty B, Ben-David M, Garber J, Merajver S, Balmanya J, Meirovitz A, Domchek S. Local Therapy in BRCA1/2 Carriers with Operable Breast Cancer: Comparison of Breast Conservation and Mastectomy. Cancer Research. 69: 959-959. DOI: 10.1158/0008-5472.Sabcs-09-959 |
0.393 |
|
| 2009 |
Kaplan J, Schnitt S, Collins L, Wang Y, Garber J, Tung N. Estrogen Rececptor (ER)-Positive Breast Cancers inBRCA1Mutation Carriers: Mutation-Related or Sporadic?: Cancer Research. 69: 5162-5162. DOI: 10.1158/0008-5472.Sabcs-09-5162 |
0.438 |
|
| 2008 |
Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA. Triple-negative breast cancer: Risk factors to potential targets Clinical Cancer Research. 14: 8010-8018. PMID 19088017 DOI: 10.1158/1078-0432.Ccr-08-1208 |
0.462 |
|
| 2008 |
Zon RT, Goss E, Vogel VG, Chlebowski RT, Jatoi I, Robson ME, Wollins DS, Garber JE, Brown P, Kramer BS. American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 986-93. PMID 19075281 DOI: 10.1200/JCO.2008.16.3691 |
0.34 |
|
| 2008 |
Saleemuddin A, Folkins AK, Garrett L, Garber J, Muto MG, Crum CP, Tworoger S. Risk factors for a serous cancer precursor (“p53 signature”) in women with inherited BRCA mutations Gynecologic Oncology. 111: 226-232. PMID 18718648 DOI: 10.1016/J.Ygyno.2008.07.018 |
0.397 |
|
| 2008 |
Folkins AK, Jarboe EA, Saleemuddin A, Lee Y, Callahan MJ, Drapkin R, Garber JE, Muto MG, Tworoger S, Crum CP. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecologic Oncology. 109: 168-73. PMID 18342932 DOI: 10.1016/j.ygyno.2008.01.012 |
0.353 |
|
| 2008 |
Gold B, Kirchhoff T, Stefanov S, Lautenberger J, Viale A, Garber J, Friedman E, Narod S, Olshen AB, Gregersen P, Kosarin K, Olsh A, Bergeron J, Ellis NA, Klein RJ, et al. Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proceedings of the National Academy of Sciences of the United States of America. 105: 4340-5. PMID 18326623 DOI: 10.1073/Pnas.0800441105 |
0.366 |
|
| 2008 |
Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, Isaacs C, Evans DG, Lynch H, Eeles RA, Neuhausen SL, Daly MB, Matloff E, Blum JL, Sabbatini P, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 1331-7. PMID 18268356 DOI: 10.1200/JCO.2007.13.9626 |
0.482 |
|
| 2008 |
Gao B, Xie XJ, Huang C, Shames DS, Chen TT, Lewis CM, Bian A, Zhang B, Olopade OI, Garber JE, Euhus DM, Tomlinson GE, Minna JD. RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers. Cancer Research. 68: 22-5. PMID 18172292 DOI: 10.1158/0008-5472.Can-07-5183 |
0.463 |
|
| 2008 |
Offit K, Garber JE. Time to check CHEK2 in families with breast cancer? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 519-20. PMID 18172189 DOI: 10.1200/JCO.2007.13.8503 |
0.41 |
|
| 2008 |
Schrader KA, Masciari S, Boyd N, Wiyrick S, Kaurah P, Senz J, Burke W, Lynch HT, Garber JE, Huntsman DG. Hereditary diffuse gastric cancer: association with lobular breast cancer. Familial Cancer. 7: 73-82. PMID 18046629 DOI: 10.1007/s10689-007-9172-6 |
0.404 |
|
| 2008 |
Schrader K, Masciari S, Boyd N, Senz J, Kaurah P, Terry MB, John E, Andrulis IL, Knight J, O'Malley FP, Daly M, Bender P, Southey MC, Hopper JL, Garber J, et al. THE ASSOCIATION OF LOBULAR BREAST CANCER WITH GERMLINE MUTATIONS OF CDH1 Clinical & Investigative Medicine. 31: 22. DOI: 10.25011/Cim.V31I4.4826 |
0.472 |
|
| 2008 |
Pierce LJ, Griffith KA, Buys S, Gaffney D, Haffty B, Moran M, Ben-David M, Garber J, Merajver SD, Meirovitz A, Domchek S. Outcomes following breast conservation versus mastectomy in BRCA1/2 carriers with early-stage breast cancer Journal of Clinical Oncology. 26: 536-536. DOI: 10.1200/Jco.2008.26.15_Suppl.536 |
0.397 |
|
| 2007 |
Antoniou AC, Sinilnikova OM, Simard J, Léoné M, Dumont M, Neuhausen SL, Struewing JP, Stoppa-Lyonnet D, Barjhoux L, Hughes DJ, Coupier I, Belotti M, Lasset C, Bonadona V, Bignon YJ, ... ... Garber JE, et al. RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. American Journal of Human Genetics. 81: 1186-200. PMID 17999359 DOI: 10.1086/522611 |
0.416 |
|
| 2007 |
Javid SH, Carlson JW, Garber JE, Birdwell RL, Lester S, Lipsitz S, Golshan M. Breast MRI wire-guided excisional biopsy: specimen size as compared to mammogram wire-guided excisional biopsy and implications for use. Annals of Surgical Oncology. 14: 3352-8. PMID 17849165 DOI: 10.1245/S10434-007-9543-0 |
0.334 |
|
| 2007 |
Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, Feltmate CM, Berkowitz RS, Muto MG. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 3985-90. PMID 17761984 DOI: 10.1200/JCO.2007.12.2622 |
0.32 |
|
| 2007 |
Bell DW, Kim SH, Godwin AK, Schiripo TA, Harris PL, Haserlat SM, Wahrer DC, Haiman CA, Daly MB, Niendorf KB, Smith MR, Sgroi DC, Garber JE, Olopade OI, Le Marchand L, et al. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. International Journal of Cancer. Journal International Du Cancer. 121: 2661-7. PMID 17721994 DOI: 10.1002/Ijc.23026 |
0.505 |
|
| 2007 |
Masciari S, Larsson N, Senz J, Boyd N, Kaurah P, Kandel MJ, Harris LN, Pinheiro HC, Troussard A, Miron P, Tung N, Oliveira C, Collins L, Schnitt S, Garber JE, et al. Germline E-cadherin mutations in familial lobular breast cancer. Journal of Medical Genetics. 44: 726-31. PMID 17660459 DOI: 10.1136/jmg.2007.051268 |
0.446 |
|
| 2007 |
Couch FJ, Sinilnikova O, Vierkant RA, Pankratz VS, Fredericksen ZS, Stoppa-Lyonnet D, Coupier I, Hughes D, Hardouin A, Berthet P, Peock S, Cook M, Baynes C, Hodgson S, Morrison PJ, ... ... Garber JE, et al. AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 16: 1416-21. PMID 17627006 DOI: 10.1158/1055-9965.EPI-07-0129 |
0.491 |
|
| 2007 |
Tchou J, Ward MR, Volpe P, Palma MD, Medina CA, Sargen M, Sonnad SS, Godwin AK, Daly M, Winchester DJ, Garber J, Weber BL, Domchek S, Nathanson KL. Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States. Clinical Breast Cancer. 7: 627-33. PMID 17592676 DOI: 10.3816/Cbc.2007.N.021 |
0.471 |
|
| 2007 |
Friebel TM, Domchek SM, Neuhausen SL, Wagner T, Evans DG, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson G, Lynch HT, Tung N, Blum JL, Weitzel J, et al. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers Clinical Breast Cancer. 7: 875-882. DOI: 10.3816/CBC.2007.n.053 |
0.469 |
|
| 2007 |
Shin JA, Gelber S, Garber J, Rosenberg R, Przypyszny M, Winer E, Partridge A. Genetic testing in young women with breast cancer: Results from a web-based survey Journal of Clinical Oncology. 25: 21093-21093. DOI: 10.1200/Jco.2007.25.18_Suppl.21093 |
0.442 |
|
| 2007 |
Garber J. S6 Breast cancer genetics: clues to tumor biology The Breast. 16: S2. DOI: 10.1016/S0960-9776(07)70029-2 |
0.402 |
|
| 2006 |
Abramson N, Costantino JP, Garber JE, Berliner N, Wickerham DL, Wolmark N. Effect of factor V Leiden and prothrombin G20210→ A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial Journal of the National Cancer Institute. 98: 904-910. PMID 16818854 DOI: 10.1093/Jnci/Djj262 |
0.358 |
|
| 2006 |
Burstein HJ, Mayer E, Patridge AH, O'Kane H, Litsas G, Come SE, Hudis CA, Goldstein DF, Muss HB, Winter EP, Garber JE. Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons. Clinical Breast Cancer. 7: 158-61. PMID 16800976 |
0.352 |
|
| 2006 |
Golshan M, Miron A, Nixon AJ, Garber JE, Cash EP, Iglehart JD, Harris JR, Wong JS. The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy. American Journal of Surgery. 192: 58-62. PMID 16769276 DOI: 10.1016/j.amjsurg.2005.12.005 |
0.49 |
|
| 2006 |
Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E, Solin LJ, Harris EE, Gaffney DK, Haffty BG, Dawson LA, Narod SA, Olivotto IA, Eisen A, Whelan TJ, Olopade OI, ... ... Garber JE, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 2437-43. PMID 16636335 DOI: 10.1200/Jco.2005.02.7888 |
0.419 |
|
| 2006 |
Smolen GA, Muir B, Mohapatra G, Barmettler A, Kim WJ, Rivera MN, Haserlat SM, Okimoto RA, Kwak E, Dahiya S, Garber JE, Bell DW, Sgroi DC, Chin L, Deng CX, et al. Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis. Cancer Research. 66: 3452-5. PMID 16585167 DOI: 10.1158/0008-5472.Can-05-4181 |
0.378 |
|
| 2006 |
Friedman E, Kotsopoulos J, Lubinski J, Lynch HT, Ghadirian P, Neuhausen SL, Isaacs C, Weber B, Foulkes WD, Moller P, Rosen B, Kim-Sing C, Gershoni-Baruch R, Ainsworth P, Daly M, ... ... Garber JE, et al. Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Research : Bcr. 8: R15. PMID 16563180 DOI: 10.1186/Bcr1387 |
0.481 |
|
| 2006 |
Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson GE, Van't Veer L, Lynch HT, Olopade OI, Weber BL, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. The Lancet. Oncology. 7: 223-9. PMID 16510331 DOI: 10.1016/S1470-2045(06)70585-X |
0.387 |
|
| 2006 |
Daly MB, Axilbund JE, Bryant E, Buys S, Eng C, Friedman S, Esserman LJ, Farrell CD, Ford JM, Garber JE, Jeter JM, Kohlmann W, Lynch PM, Marcom PK, Nabell LM, et al. Genetic/familial high-risk assessment: breast and ovarian. Journal of the National Comprehensive Cancer Network : Jnccn. 4: 156-76. PMID 16451772 DOI: 10.6004/jnccn.2006.0016 |
0.349 |
|
| 2006 |
Digianni LM, Rue M, Emmons K, Garber JE. Complementary medicine use before and 1 year following genetic testing for BRCA1/2 mutations. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 15: 70-5. PMID 16434589 DOI: 10.1158/1055-9965.EPI-05-0646 |
0.302 |
|
| 2006 |
Wong P, Verselis SJ, Garber JE, Schneider K, DiGianni L, Stockwell DH, Li FP, Syngal S. Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. Gastroenterology. 130: 73-9. PMID 16401470 DOI: 10.1053/J.GASTRO.2005.10.014 |
0.327 |
|
| 2006 |
Colilla S, Kantoff PW, Neuhausen SL, Godwin AK, Daly MB, Narod SA, Garber JE, Lynch HT, Brown M, Weber BL, Rebbeck TR. The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers. Carcinogenesis. 27: 599-605. PMID 16244359 DOI: 10.1093/Carcin/Bgi246 |
0.429 |
|
| 2006 |
Kandel MJ, Stadler Z, Masciari S, Collins L, Schnitt S, Harris L, Miron A, Richardson A, Garber JE. Prevalence of BRCA1 mutations in triple negative breast cancer (BC) Journal of Clinical Oncology. 24: 508-508. DOI: 10.1200/JCO.2006.24.18_SUPPL.508 |
0.419 |
|
| 2006 |
Masciari S, Kandel M, Digianni L, Dillon D, Li F, Garber J. Histopathological features of breast cancers in women with germline TP53 mutations Journal of Clinical Oncology. 24: 10031-10031. DOI: 10.1200/Jco.2006.24.18_Suppl.10031 |
0.429 |
|
| 2005 |
Larson PS, Schlechter BL, de las Morenas A, Garber JE, Cupples LA, Rosenberg CL. Allele imbalance, or loss of heterozygosity, in normal breast epithelium of sporadic breast cancer cases and BRCA1 gene mutation carriers is increased compared with reduction mammoplasty tissues. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 8613-9. PMID 16314623 DOI: 10.1200/Jco.2005.02.1451 |
0.484 |
|
| 2005 |
Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van 't Veer L, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7804-10. PMID 16219936 DOI: 10.1200/Jco.2004.00.8151 |
0.455 |
|
| 2005 |
Kotsopoulos J, Lubinski J, Lynch HT, Neuhausen SL, Ghadirian P, Isaacs C, Weber B, Kim-Sing C, Foulkes WD, Gershoni-Baruch R, Ainsworth P, Friedman E, Daly M, Garber JE, Karlan B, et al. Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes & Control : Ccc. 16: 667-74. PMID 16049805 DOI: 10.1007/S10552-005-1724-1 |
0.455 |
|
| 2005 |
Kurian AW, Mills MA, Jaffee M, Sigal BM, Chun NM, Kingham KE, Collins LC, Nowels KW, Plevritis SK, Garber JE, Ford JM, Hartman AR. Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 14: 1082-9. PMID 15894656 DOI: 10.1158/1055-9965.Epi-04-0776 |
0.403 |
|
| 2005 |
Garber JE, Offit K. Hereditary cancer predisposition syndromes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 276-92. PMID 15637391 DOI: 10.1200/JCO.2005.10.042 |
0.389 |
|
| 2005 |
Garber JE, Halabi S, Kaplan E, Edge S, Dressler L, Paskett E, Berliner N. Factor V Leiden (FVL) mutations and thromboembolic events (TE) in women with breast cancer on adjuvant tamoxifen Journal of Clinical Oncology. 23: 508-508. DOI: 10.1200/Jco.2005.23.16_Suppl.508 |
0.34 |
|
| 2005 |
Masciari S, Harris L, Branda K, Petkovska A, Paez J, Haber D, Digianni L, Sellers W, Li F, Garber J. Germline TP53 mutations in women with very early onset breast cancer (BR) Journal of Clinical Oncology. 23: 1015-1015. DOI: 10.1200/Jco.2005.23.16_Suppl.1015 |
0.403 |
|
| 2004 |
Diller L, Mauch P, Medeiros Nancarrow C, Byrnes L, Stevenson MA, Ng A, Garber J. A feasibility study of tamoxifen chemoprevention in Hodgkin's disease (HD) survivors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 8551. PMID 28013897 DOI: 10.1200/jco.2004.22.14_suppl.8551 |
0.34 |
|
| 2004 |
Schneider KA, DiGianni LM, Patenaude AF, Klar N, Stopfer JE, Calzone KA, Li FP, Weber BL, Garber JE. Accuracy of cancer family histories: comparison of two breast cancer syndromes. Genetic Testing. 8: 222-8. PMID 15727243 DOI: 10.1089/Gte.2004.8.222 |
0.459 |
|
| 2004 |
Jernström H, Lubinski J, Lynch HT, Ghadirian P, Neuhausen S, Isaacs C, Weber BL, Horsman D, Rosen B, Foulkes WD, Friedman E, Gershoni-Baruch R, Ainsworth P, Daly M, Garber J, et al. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Journal of the National Cancer Institute. 96: 1094-8. PMID 15265971 DOI: 10.1093/Jnci/Djh211 |
0.476 |
|
| 2004 |
Lubinski J, Phelan CM, Ghadirian P, Lynch HT, Garber J, Weber B, Tung N, Horsman D, Isaacs C, Monteiro AN, Sun P, Narod SA. Cancer variation associated with the position of the mutation in the BRCA2 gene. Familial Cancer. 3: 1-10. PMID 15131399 DOI: 10.1023/B:Fame.0000026816.32400.45 |
0.43 |
|
| 2004 |
Balmaña J, Stoffel EM, Emmons KM, Garber JE, Syngal S. Comparison of motivations and concerns for genetic testing in hereditary colorectal and breast cancer syndromes Journal of Medical Genetics. 41. PMID 15060120 DOI: 10.1136/jmg.2003.012526 |
0.429 |
|
| 2004 |
Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van 't Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 1055-62. PMID 14981104 DOI: 10.1200/Jco.2004.04.188 |
0.484 |
|
| 2004 |
Diller L, Mauch P, Nancarrow CM, Byrnes L, Stevenson MA, Ng A, Garber J. A feasibility study of tamoxifen chemoprevention in Hodgkin's disease (HD) survivors Journal of Clinical Oncology. 22: 8551-8551. DOI: 10.1200/Jco.2004.22.90140.8551 |
0.314 |
|
| 2003 |
Garber JE. Breast cancer screening: a final analysis? Ca: a Cancer Journal For Clinicians. 53: 138-40. PMID 12809407 DOI: 10.3322/CANJCLIN.53.3.138 |
0.405 |
|
| 2003 |
Leibowitz SB, Garber JE, Fox EA, Loda M, Kaufman DS, Kantoff PW, Oh WK. Male patients with diagnoses of both breast cancer and prostate cancer. The Breast Journal. 9: 208-12. PMID 12752629 DOI: 10.1046/j.1524-4741.2003.09312.x |
0.373 |
|
| 2003 |
Stoffel EM, Garber JE, Grover S, Russo L, Johnson J, Syngal S. Cancer surveillance is often inadequate in people at high risk for colorectal cancer. Journal of Medical Genetics. 40: e54. PMID 12746408 DOI: 10.1136/JMG.40.5.E54 |
0.338 |
|
| 2003 |
Garber J. Implications of genetic information at breast cancer diagnosis The Breast. 12: S6-S7. DOI: 10.1016/S0960-9776(03)80017-6 |
0.409 |
|
| 2003 |
Karlan BY, Boyd J, Strong L, Garber J, Fountain J, Beller U. Discussion: Hereditary Ovarian Cancer Gynecologic Oncology. 88. DOI: 10.1006/Gyno.2002.6675 |
0.317 |
|
| 2002 |
Narod SA, Dubé MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, Provencher D, Heimdal K, Moller P, Robson M, Offit K, Isaacs C, Weber B, Friedman E, Gershoni-Baruch R, ... ... Garber JE, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Journal of the National Cancer Institute. 94: 1773-9. PMID 12464649 DOI: 10.1093/Jnci/94.23.1773 |
0.491 |
|
| 2002 |
Euhus DM, Smith KC, Robinson L, Stucky A, Olopade OI, Cummings S, Garber JE, Chittenden A, Mills GB, Rieger P, Esserman L, Crawford B, Hughes KS, Roche CA, Ganz PA, et al. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. Journal of the National Cancer Institute. 94: 844-51. PMID 12048272 DOI: 10.1093/Jnci/94.11.844 |
0.327 |
|
| 2002 |
Berry DA, Iversen ES, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, Rubinstein WS, Hughes KS, Parmigiani G. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes Journal of Clinical Oncology. 20: 2701-2712. PMID 12039933 DOI: 10.1200/Jco.2002.05.121 |
0.451 |
|
| 2002 |
Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. The New England Journal of Medicine. 346: 1616-22. PMID 12023993 DOI: 10.1056/Nejmoa012158 |
0.447 |
|
| 2002 |
Diller L, Medeiros Nancarrow C, Shaffer K, Matulonis U, Mauch P, Neuberg D, Tarbell NJ, Litman H, Garber J. Breast cancer screening in women previously treated for Hodgkin's disease: a prospective cohort study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 2085-91. PMID 11956269 DOI: 10.1200/Jco.2002.08.031 |
0.414 |
|
| 2001 |
Runnebaum IB, Wang-Gohrke S, Vesprini D, Kreienberg R, Lynch H, Moslehi R, Ghadirian P, Weber B, Godwin AK, Risch H, Garber J, Lerman C, Olopade OI, Foulkes WD, Karlan B, et al. Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics. 11: 635-8. PMID 11668223 DOI: 10.1097/00008571-200110000-00010 |
0.449 |
|
| 2001 |
Ang P, Garber JE. Genetic susceptibility for breast cancer--risk assessment and counseling. Seminars in Oncology. 28: 419-33. PMID 11498834 DOI: 10.1016/S0093-7754(01)90134-4 |
0.43 |
|
| 2001 |
Ang P, Garber JE. Genetic susceptibility for breast cancer[mdash ]Risk assessment and counseling Seminars in Oncology. 28: 419-433. DOI: 10.1053/sonc.2001.26152 |
0.443 |
|
| 2001 |
Ang P, Schrag D, Schneider K, Shannon K, Johnson J, Hiller E, Emmons K, Garber J, Syngal S. Colorectal cancer knowledge and screening rates are lower than for breast cancer even in individuals at high risk of cancer Gastroenterology. 120. DOI: 10.1016/S0016-5085(08)83692-X |
0.422 |
|
| 2000 |
Pierce LJ, Strawderman M, Narod SA, Oliviotto I, Eisen A, Dawson L, Gaffney D, Solin LJ, Nixon A, Garber J, Berg C, Isaacs C, Heimann R, Olopade OI, Haffty B, et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 3360-9. PMID 11013276 DOI: 10.1200/Jco.2000.18.19.3360 |
0.423 |
|
| 2000 |
Syngal S, Fox EA, Eng C, Kolodner RD, Garber JE. Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. Journal of Medical Genetics. 37: 641-5. PMID 10978352 DOI: 10.1136/Jmg.37.9.641 |
0.313 |
|
| 2000 |
Lu KH, Garber JE, Cramer DW, Welch WR, Niloff J, Schrag D, Berkowitz RS, Muto MG. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 2728-32. PMID 10894872 DOI: 10.1200/JCO.2000.18.14.2728 |
0.403 |
|
| 2000 |
Rohlfs EM, Puget N, Graham ML, Weber BL, Garber JE, Skrzynia C, Halperin JL, Lenoir GM, Silverman LM, Mazoyer S. An Alu-mediated 7.1 kb deletion of BRCA1 exons 8 and 9 in breast and ovarian cancer families that results in alternative splicing of exon 10 Genes Chromosomes and Cancer. 28: 300-307. PMID 10862036 DOI: 10.1002/1098-2264(200007)28:3<300::Aid-Gcc8>3.0.Co;2-1 |
0.4 |
|
| 2000 |
Schrag D, Kuntz KM, Garber JE, Weeks JC. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations Journal of the American Medical Association. 283: 617-624. PMID 10665701 DOI: 10.1001/JAMA.283.5.617 |
0.512 |
|
| 2000 |
Shafman TD, Levitz S, Nixon AJ, Gibans LA, Nichols KE, Bell DW, Ishioka C, Isselbacher KJ, Gelman R, Garber J, Harris JR, Haber DA. Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor. Genes, Chromosomes & Cancer. 27: 124-9. PMID 10612799 DOI: 10.1002/(Sici)1098-2264(200002)27:2<124::Aid-Gcc2>3.0.Co;2-M |
0.473 |
|
| 2000 |
Stoffel EM, Garber J, Johnson J, Syngal S. Cancer surveillance is often inadequate in individuals at high risk for colorectal cancer (CRC) The American Journal of Gastroenterology. 95: 2552-2552. DOI: 10.1111/j.1572-0241.2000.02843.x |
0.322 |
|
| 2000 |
Stoffel EM, Garber J, Johnson J, Syngal S. Cancer surveillance is often inadequate in individuals at high risk for colorectal cancer (CRC) The American Journal of Gastroenterology. 95: 2552-2552. DOI: 10.1016/S0002-9270(00)01635-X |
0.322 |
|
| 1999 |
Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science (New York, N.Y.). 286: 2528-31. PMID 10617473 DOI: 10.1126/Science.286.5449.2528 |
0.362 |
|
| 1999 |
Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Isaacs C, Olopade O, Garber JE, Godwin AK, Daly MB, Narod SA, Neuhausen SL, Lynch HT, Weber BL. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. Journal of the National Cancer Institute. 91: 1475-9. PMID 10469748 DOI: 10.1093/Jnci/91.17.1475 |
0.502 |
|
| 1999 |
Quesnel S, Verselis S, Portwine C, Garber J, White M, Feunteun J, Malkin D, Li FP. p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome. Oncogene. 18: 3970-8. PMID 10435620 DOI: 10.1038/Sj.Onc.1202783 |
0.346 |
|
| 1999 |
Audrain J, Rimer B, Cella D, Stefanek M, Garber J, Pennanen M, Helzlsouer K, Vogel V, Lin TH, Lerman C. The impact of a brief coping skills intervention on adherence to breast self-examination among first-degree relatives of newly diagnosed breast cancer patients. Psycho-Oncology. 8: 220-9. PMID 10390734 DOI: 10.1002/(Sici)1099-1611(199905/06)8:3<220::Aid-Pon370>3.0.Co;2-C |
0.44 |
|
| 1999 |
Rebbeck TR, Kantoff PW, Krithivas K, Neuhausen S, Blackwood MA, Godwin AK, Daly MB, Narod SA, Garber JE, Lynch HT, Weber BL, Brown M. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. American Journal of Human Genetics. 64: 1371-7. PMID 10205268 DOI: 10.1086/302366 |
0.48 |
|
| 1999 |
Wong J, Garber J, Nixon A, Gelman R, Recht A, Galper S, Silver B, Harris J. 163 Contralateral breast cancer after conservative surgery and radiation therapy in early-stage breast cancer International Journal of Radiation Oncology*Biology*Physics. 45: 231-232. DOI: 10.1016/S0360-3016(99)90181-5 |
0.394 |
|
| 1998 |
Syngal S, Weeks JC, Schrag D, Garber JE, Kuntz KM. Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations Annals of Internal Medicine. 129: 787-796. PMID 9841584 DOI: 10.7326/0003-4819-129-10-199811150-00007 |
0.354 |
|
| 1998 |
Schwartz MD, Lerman C, Audrain J, Cella D, Rimer B, Stefanek M, Garber J, Lin TH, Vogel V. The impact of a brief problem-solving training intervention for relatives of recently diagnosed breast cancer patients. Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine. 20: 7-12. PMID 9755346 DOI: 10.1007/Bf02893803 |
0.338 |
|
| 1998 |
FitzGerald MG, Marsh DJ, Wahrer D, Bell D, Caron S, Shannon KE, Ishioka C, Isselbacher KJ, Garber JE, Eng C, Haber DA. Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer. Oncogene. 17: 727-31. PMID 9715274 DOI: 10.1038/Sj.Onc.1201984 |
0.488 |
|
| 1998 |
Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, Antman K, Russo D, Wood ME, Mullineau L, Isaacs C, Peshkin B, Buys S, Venne V, Rowley PT, et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 2417-25. PMID 9667259 DOI: 10.1200/Jco.1998.16.7.2417 |
0.469 |
|
| 1998 |
Chabner E, Nixon A, Gelman R, Hetelekidis S, Recht A, Bornstein B, Connolly J, Schnitt S, Silver B, Manola J, Harris J, Garber J. Family history and treatment outcome in young women after breast-conserving surgery and radiation therapy for early-stage breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 2045-51. PMID 9626202 DOI: 10.1200/Jco.1998.16.6.2045 |
0.436 |
|
| 1998 |
Brunet JS, Ghadirian P, Rebbeck TR, Lerman C, Garber JE, Tonin PN, Abrahamson J, Foulkes WD, Daly M, Wagner-Costalas J, Godwin A, Olopade OI, Moslehi R, Liede A, Futreal PA, et al. Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. Journal of the National Cancer Institute. 90: 761-6. PMID 9605646 DOI: 10.1093/Jnci/90.10.761 |
0.429 |
|
| 1998 |
Garber J. Inherited breast cancer: increasingly familiar territory. Journal of Clinical Oncology. 16: 1639-1641. PMID 9586872 DOI: 10.1200/Jco.1998.16.5.1639 |
0.453 |
|
| 1998 |
Neuhausen SL, Godwin AK, Gershoni-Baruch R, Schubert E, Garber J, Stoppa-Lyonnet D, Olah E, Csokay B, Serova O, Lalloo F, Osorio A, Stratton M, Offit K, Boyd J, Caligo MA, et al. Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. American Journal of Human Genetics. 62: 1381-8. PMID 9585613 DOI: 10.1086/301885 |
0.415 |
|
| 1998 |
Audrain J, Rimer B, Cella D, Garber J, Peshkin BN, Ellis J, Schildkraut J, Stefanek M, Vogel V, Lerman C. Genetic counseling and testing for breast-ovarian cancer susceptibility: what do women want? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 133-8. PMID 9440734 DOI: 10.1200/Jco.1998.16.1.133 |
0.47 |
|
| 1998 |
Shafman TD, Nixon AJ, Levitz S, Gibans L, Nichols KE, Bell D, Isselbacher KJ, Manola J, Gelman R, Garber J, Haber DA, Harris JR. Prevalence of ataxia-telangiectasia heterozygosity in patients developing contralateral breast cancer following treatment with conservative surgery and radiation therapy International Journal of Radiation Oncology*Biology*Physics. 42: 253. DOI: 10.1016/S0360-3016(98)80359-3 |
0.322 |
|
| 1998 |
Olopade OI, Offit K, Garber JE. Genetic Testing for Susceptibility to Cancer Jama. 279: 1612-1613. DOI: 10.1001/Jama.279.20.1612 |
0.31 |
|
| 1997 |
Garber JE. Validation of family history of breast cancer and identification of the BRCA1 and other syndromes using a population-based cancer registry. Journal of Women's Health. 6: 349-51. PMID 9201670 DOI: 10.1089/JWH.1997.6.349 |
0.43 |
|
| 1997 |
Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis - Effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations New England Journal of Medicine. 336: 1465-1471. PMID 9148160 DOI: 10.1056/NEJM199705153362022 |
0.397 |
|
| 1997 |
Chabner E, Nixon A, Garber J, Gelman R, Bornstein B, Connolly J, Hetelekidis S, Recht A, Schnitt S, Silver B, Harris J. 5 Family history suggestive of an inherited susceptibility to breast cancer and treatment outcome in young women after breast-conserving therapy International Journal of Radiation Oncology Biology Physics. 39: 137. DOI: 10.1016/S0360-3016(97)80562-7 |
0.397 |
|
| 1997 |
Burke W, Daly M, Garber J, Botkin J, Lynch P, Mctiernan A, Offit K, Perlman JA, Petersen GM, Thomson E. Benefits and Risks of Screening Mammography in Women With BRCA1 and BRCA2 Mutations-Reply Jama. 278: 289-290. DOI: 10.1001/Jama.1997.03550040046031 |
0.472 |
|
| 1997 |
Burke W, Daly M, Garber J, Botkin J, Kahn MJE, Lynch P, McTiernan A, Offit K, Perlman J, Petersen G, Thomson E, Varricchio C. Recommendations for follow-up care of individuals with an inherited predisposition to Cancer. II. BRCA1 and BRCA2 Jama. 277: 997-1003. DOI: 10.1001/Jama.1997.03540360065034 |
0.485 |
|
| 1997 |
Burke W, Petersen GM, Lynch P, Botkin J, Daly M, Garber J, Kahn MJE, McTiernan A, Offit K, Thomson E, Varricchio C. Recommendations for Follow-up Care of Individuals With an Inherited Predisposition to Cancer: I. Hereditary Nonpolyposis Colon Cancer Jama. 277: 915-919. DOI: 10.1001/Jama.1997.03540350065035 |
0.408 |
|
| 1996 |
Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, LiVolsi VA, Berchuck A, Muto MG, Garber JE, Weber BL, Lynch HT, Boyd J. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. The New England Journal of Medicine. 335: 1413-6. PMID 8875917 DOI: 10.1056/Nejm199611073351901 |
0.371 |
|
| 1996 |
Couch FJ, Farid LM, DeShano ML, Tavtigian SV, Calzone K, Campeau L, Peng Y, Bogden B, Chen Q, Neuhausen S, Shattuck-Eidens D, Godwin AK, Daly M, Radford DM, Sedlacek S, ... ... Garber J, et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nature Genetics. 13: 123-5. PMID 8673091 DOI: 10.1038/Ng0596-123 |
0.483 |
|
| 1996 |
FitzGerald MG, MacDonald DJ, Krainer M, Hoover I, O'Neil E, Unsal H, Silva-Arrieto S, Finkelstein DM, Beer-Romero P, Englert C, Sgroi DC, Smith BL, Younger JW, Garber JE, Duda RB, et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. The New England Journal of Medicine. 334: 143-9. PMID 8531968 DOI: 10.1056/Nejm199601183340302 |
0.486 |
|
| 1996 |
Garber JE. Testing for Inherited Cancer Susceptibility Jama: the Journal of the American Medical Association. 275: 1928. DOI: 10.1001/JAMA.1996.03530480070043 |
0.334 |
|
| 1995 |
Hoskins KF, Stopfer JE, Calzone KA, Weber BL, Merajver SD, Rebbeck TR, Garber JE. Assessment and Counseling for Women With a Family History of Breast Cancer: A Guide for Clinicians Jama: the Journal of the American Medical Association. 273: 577-585. PMID 7837392 DOI: 10.1001/Jama.1995.03520310075033 |
0.456 |
|
| 1994 |
Castilla LH, Couch FJ, Erdos MR, Hoskins KF, Calzone K, Garber JE, Boyd J, Lubin MB, Deshano ML, Brody LC, Collins FS, Weber BL. Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer Nature Genetics. 8: 387-391. PMID 7894491 DOI: 10.1038/Ng1294-387 |
0.388 |
|
| 1993 |
Biesecker BB, Boehnke M, Calzone K, Markel DS, Garber JE, Collins FS, Weber BL. Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. Jama. 269: 1970-4. PMID 8352830 |
0.458 |
|
| 1993 |
Weber BL, Garber JE. Family History and Breast Cancer: Probabilities and Possibilities Jama. 270: 1602-1603. DOI: 10.1001/Jama.1993.03510130108041 |
0.457 |
|
| 1992 |
Malkin D, Jolly KW, Barbier N, Look AT, Friend SH, Gebhardt MC, Andersen TI, Børresen AL, Li FP, Garber J, Strong LC. Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms New England Journal of Medicine. 326: 1309-1315. PMID 1565144 DOI: 10.1056/NEJM199205143262002 |
0.378 |
|
| 1992 |
Garber JE. Book Review Oral Contraceptives and Breast Cancer By a committee of the Institute of Medicine. 185 pp. Washington, D.C., National Academy Press, 1991. $24.95. New England Journal of Medicine. 326: 715-716. DOI: 10.1056/NEJM199203053261020 |
0.332 |
|
| 1990 |
Garber JE, Burke EM, Lavally BL, Billett AL, Sallan SE, Scott RM, Kupsky W, Li FP. Choroid plexus tumors in the breast cancer-sarcoma syndrome. Cancer. 66: 2658-60. PMID 2249207 DOI: 10.1002/1097-0142(19901215)66:12<2658::AID-CNCR2820661232>3.0.CO;2-C |
0.352 |
|
| 1989 |
Garber JE, Craig Henderson I. The Use of Chemotherapy in Metastatic Breast Cancer Hematology/Oncology Clinics of North America. 3: 807-821. DOI: 10.1016/S0889-8588(18)30532-X |
0.424 |
|
| Show low-probability matches. |